



**Congressional  
Research Service**

Informing the legislative debate since 1914

---

# Patent Litigation Reform Legislation in the 114<sup>th</sup> Congress

**Brian T. Yeh**

Legislative Attorney

**Emily M. Lanza**

Legislative Attorney

February 8, 2016

**Congressional Research Service**

7-5700

[www.crs.gov](http://www.crs.gov)

R43979

## Summary

This report describes how current patent litigation reform legislation would change existing patent law to address the perceived problems caused by entities that engage in patent litigation tactics that have been criticized as abusive or deceptive. The bills introduced in the 114<sup>th</sup> Congress include the Innovation Act (H.R. 9), Protecting American Talent and Entrepreneurship Act (PATENT) Act (S. 1137), Demand Letter Transparency Act of 2015 (H.R. 1896), Targeting Rogue and Opaque Letters (TROL) Act (H.R. 2045), and the Support Technology and Research for Our Nation's Growth (STRONG) Patents Act of 2015 (S. 632). The legislation includes the following changes to the patent system:

**Heightened Pleading Requirements:** The Innovation Act and the PATENT Act would require parties alleging patent infringement in a civil action to include in the court pleadings specified details concerning each claim of each patent infringed, and the acts of the alleged infringer.

**Limits on Discovery:** The Innovation Act (as reported by the House Judiciary Committee) and the PATENT Act propose limitations on discovery pending the resolution of certain motions, including motions to dismiss, transfer venue, and drop parties.

**Transparency of Patent Ownership:** The Innovation Act and the PATENT Act would require plaintiffs in patent cases to disclose to the United States Patent and Trademark Office (USPTO), the court, and all adverse parties information relating to entities that own or have a financial interest in the patent.

**Customer-Suit Exception:** The Innovation Act and the PATENT Act would allow a court to stay litigation against a customer of a product that contains allegedly infringing technologies, if the manufacturer of the product is a party to the same or other action on the same patent and other requirements are satisfied.

**Shifting of Attorney Fees:** The Innovation Act would require a district court to award attorney fees to a prevailing party in patent cases, unless the court finds that the nonprevailing party's position and conduct "were reasonably justified in law and fact or that special circumstances ... make an award unjust." The PATENT Act would require the prevailing party to make a motion to the court to determine whether the nonprevailing party's position and conduct were "objectively reasonable"; if they were not, then the court must award reasonable attorney fees to the prevailing party unless there are special circumstances that would make an award unjust.

**Fee Recovery:** The Innovation Act and the PATENT Act contain provisions that address the situation when the nonprevailing party alleging infringement is unable to pay the fee award and other expenses. The Innovation Act (as reported) and the PATENT Act would allow a defendant to submit a statement early in the litigation claiming that the plaintiff's primary business is the assertion and enforcement of patents; the plaintiff would then need to certify that it has sufficient funds to satisfy any potential award of attorney fees that may be assessed, and to identify (and provide notice to) any "interested parties" that could be held accountable for the award if the plaintiffs are unable to pay it.

**Demand Letters:** Several bills propose various approaches to address demand letters. The STRONG Patents Act and the TROL Act would impose specific enforcement and content requirements for demand letters. The Innovation Act expresses the sense of Congress that purposely evasive demand letters are abusing the patent system in a manner contrary to public policy. The Demand Letter Transparency Act proposes both disclosure and content requirements directed towards "abusive" demand letter practices, and the PATENT Act focuses on pre-suit notifications.

**Post-Grant Review Reforms:** The Innovation Act, PATENT Act (as reported by the Senate Judiciary Committee), and the STRONG Patents Act would mandate that the Patent Trial and Appeal Board (PTAB), in inter partes review (IPR) and post-grant review (PGR) proceedings, follow the same claim construction standard used by district courts. The Innovation Act and the PATENT Act (as reported) would require the PTAB to consider prior claim construction by a court in a civil action in which the patent owner was a party. In addition, the Innovation Act and the PATENT Act would narrow the estoppel effect arising from a PGR. The Innovation Act (as reported) and the STRONG Patents Act would heighten the standing requirements for persons wanting to initiate a PGR or IPR. The STRONG Patents Act would also require the IPR/PGR petitioner to prove unpatentability of a patent claim by “clear and convincing evidence.”

**Elimination of USPTO Fee Diversion:** The STRONG Patents Act would permit the USPTO to spend all fee revenue that it collects without further appropriation action or fiscal year limitation.

**Venue:** The Innovation Act (as reported) would impose limitations on the judicial districts in which a civil action may be brought for patent infringement or for a declaratory judgment that a patent is invalid or not infringed.

**Assistance for Small Businesses:** The Innovation Act, STRONG Patents Act, and the PATENT Act contain provisions designed to help small businesses that participate in the patent system either as patent owners or as defendants.

## Contents

Introduction .....	1
Background .....	2
Patent Law Fundamentals .....	2
Patent Assertion Entities .....	5
Legislation in the 114 <sup>th</sup> Congress .....	6
Heightened Pleading Requirements .....	7
Limits on Discovery and Cost-Shifting.....	9
Transparency of Patent Ownership .....	11
Stays of Litigation Brought Against Infringing Customers.....	14
Shifting of Attorney Fees .....	16
Recovery of Fee Awards from Interested Parties .....	19
Demand Letters .....	24
Reforms of Patent Trial and Appeal Board’s Proceedings (IPR and PGR).....	27
Ending Diversion of USPTO Fees .....	33
Venue.....	34
Provisions Concerning Small Businesses .....	35

## Tables

Table 1. Patent Litigation Reform Legislation in the 114 <sup>th</sup> Congress.....	37
--	----

## Contacts

Author Contact Information .....	48
----------------------------------	----

## Introduction<sup>1</sup>

Congress has shown significant interest in altering the current patent system in response to concerns about entities that engage in patent litigation tactics that have been criticized as abusive or deceptive. Many congressional hearings on the topic of patent litigation abuse have been held in the 114<sup>th</sup> and 113<sup>th</sup> Congresses,<sup>2</sup> and several legislative proposals have been introduced;<sup>3</sup> one bill in the 113<sup>th</sup> Congress, H.R. 3309, the Innovation Act, was passed by the House in December 2013. In June 2015, the House Judiciary Committee approved the Innovation Act (H.R. 9) by a vote of 24 to 8, and the Senate Judiciary Committee passed the PATENT Act (S. 1137) by a vote of 16 to 4; both bills are awaiting floor action.<sup>4</sup> This report describes how the major provisions of current patent litigation reform legislation, with a particular focus on these two bills that have seen the most legislative activity, would change existing patent law to address the perceived problems in the patent litigation system.

<sup>1</sup> Portions of this report have been borrowed and adapted from CRS Report R42668, *An Overview of the “Patent Trolls” Debate*, by Brian T. Yeh and CRS Report R43321, *Patent Infringement Pleadings: An Analysis of Recent Proposals for Patent Reform*, by Emily M. Lanza.

<sup>2</sup> H.R. 9, the Innovation Act: Hearing Before the House Judiciary Comm., 114<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2015); S. 1137, the “PATENT ACT”—Finding Effective Solutions to Address Abusive Patent Practices: Hearing Before the Senate Judiciary Comm., 114<sup>th</sup> Cong. 1<sup>st</sup> Sess. (2015); H.R. \_\_\_, the Targeting Rogue and Opaque Letters Act (TROL Act): Hearing Before the House Energy & Commerce Comm., Subcomm. on Commerce, Manufacturing, and Trade, 114<sup>th</sup> Cong. 1<sup>st</sup> Sess. (2015); Patent Reform: Protecting American Innovators and Job Creators from Abusive Patent Litigation: Hearing Before the House Judiciary Comm., Subcomm. on Courts, Intellectual Property and Internet, 114<sup>th</sup> Cong. 1<sup>st</sup> Sess. (2015); The Impact of Abusive Patent Litigation Practices on the American Economy: Hearing Before the Senate Judiciary Comm., 114<sup>th</sup> Cong. 1<sup>st</sup> Sess. (2015); Patent Reform: Protecting Innovation and Entrepreneurship: Hearing Before the Senate Comm. on Small Business & Entrepreneurship, 114<sup>th</sup> Cong. 1<sup>st</sup> Sess. (2015); Trolling for a Solution: Ending Abusive Patent Demand Letters: Hearing Before the House Energy & Commerce Comm., Subcomm. on Commerce, Manufacturing, and Trade, 113<sup>th</sup> Cong. 2d Sess. (2014); H.R. 3309, the “Innovation Act:” Hearing Before the House Judiciary Comm., 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013); Protecting Small Businesses and Promoting Innovation by Limiting Patent Troll Abuse: Hearing Before the Senate Judiciary Comm., 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013); The Impact of Patent Assertion Entities on Innovation and the Economy: Hearing Before the House Energy and Commerce Comm., Subcomm. on Oversight and Investigations, 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013); Demand Letters and Consumer Protection: Examining Deceptive Practices by Patent Assertion Entities: Hearing Before the Senate Commerce, Science, & Transportation Comm., Subcomm. on Consumer Protection, Product Safety, and Insurance, 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013); Abusive Patent Litigation: The Issues Impacting American Competitiveness and Job Creation at the International Trade Commission and Beyond: Hearing Before the House Judiciary Comm., Subcomm. on Courts, Intellectual Property, and the Internet, 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013); Abusive Patent Litigation: The Impact on American Innovation & Jobs, and Potential Solutions: Hearing Before the House Judiciary Comm., Subcomm. on Courts, Intellectual Property, and the Internet, 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013).

<sup>3</sup> In the 114<sup>th</sup> Congress, introduced legislation includes the Innovation Act (H.R. 9), Protecting American Talent and Entrepreneurship Act (PATENT) Act (S. 1137), Demand Letter Transparency Act of 2015 (H.R. 1896), Targeting Rogue and Opaque Letters (TROL) Act (H.R. 2045), and the Support Technology and Research for Our Nation’s Growth (STRONG) Patents Act of 2015 (S. 632). In the 113<sup>th</sup> Congress, legislation that was introduced but not enacted included the following: the Innovation Act (H.R. 3309), Transparency in Assertion of Patents Act (S. 2049), the Patent Transparency and Improvements Act of 2013 (S. 1720), the Patent Abuse Reduction Act of 2013 (S. 1013), the Patent Litigation Integrity Act of 2013 (S. 1612), the Demand Letter Transparency Act of 2013 (H.R. 3540), Patent Litigation and Innovation Act of 2013 (H.R. 2639), End of Anonymous Patents Act (H.R. 2024), and the Saving High-Tech Innovators from Egregious Legal Disputes (SHIELD) Act of 2013 (H.R. 845).

<sup>4</sup> The House Judiciary Committee reported H.R. 9 on July 29, 2015, *see* H.Rept. 114-235. The Senate Judiciary Committee reported S. 1137 on September 8, 2015.

## Background

### Patent Law Fundamentals

According to Section 101 of the Patent Act, one who “invents or discovers any new and useful process, machine, manufacture, or any composition of matter, or any new and useful improvement thereof, may obtain a patent therefore, subject to the conditions and requirements of this title.”<sup>5</sup> Thus, in order for an invention to qualify for patent protection, it must fall within one of the four statutory categories of patent-eligible subject matter: processes, machines, manufactures, and compositions of matter. However, the U.S. Supreme Court has articulated certain limits to Section 101 of the Patent Act, stating that “laws of nature, natural phenomena, and abstract ideas” may not be patented.<sup>6</sup>

The U.S. Patent and Trademark Office (USPTO) issues a patent to an inventor after USPTO examiners approve the submitted patent application for an allegedly new invention.<sup>7</sup> An application for a patent consists of two primary parts: (1) a “specification,” which is a written description of the invention enabling those skilled in the art to practice the invention, and (2) one or more claims that define the scope of the subject matter which the applicant regards as his invention.<sup>8</sup> Therefore, these claims define the scope of the patentee’s rights under the patent.<sup>9</sup>

Before a patent may be granted, the USPTO examiners must find that the new invention satisfies several substantive requirements that are set forth in the Patent Act.<sup>10</sup> For example, one of the statutory requirements for patentability of an invention is “novelty.”<sup>11</sup> For an invention to be considered “novel,” the subject matter must be different than, and not be wholly “anticipated” by, the so-called “prior art,” or public domain materials such as publications and other patents. Another statutory requirement is that the subject matter of an alleged invention must be “nonobvious” at the time of its creation. A patent claim is invalid if “the differences between the subject matter sought to be patented and the prior art<sup>12</sup> are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains.”<sup>13</sup> Finally, the invention must also be “useful,” which means that the invention provides a “significant and presently available,” “well-defined and particular benefit to the public.”<sup>14</sup>

The Patent Act grants patent holders the exclusive right to exclude others from making, using, offering for sale, or selling their patented invention throughout the United States, or importing the

---

<sup>5</sup> 35 U.S.C. §101.

<sup>6</sup> *Diamond v. Diehr*, 450 U.S. 175, 185 (1981).

<sup>7</sup> 35 U.S.C. §131.

<sup>8</sup> *Id.* §112.

<sup>9</sup> 3-8 DONALD S. CHISUM, CHISUM ON PATENTS §8.01 (2006).

<sup>10</sup> 35 U.S.C. §§102, 103(a).

<sup>11</sup> *Id.* §102.

<sup>12</sup> “Prior art” is a legal term of art that refers to the materials (usually called “references” in patent law) that comprise the available knowledge regarding the subject matter of the invention sought to be patented, such as other issued patents, publications, and evidence of actual uses or sales of the technology. ROGER SCHECHTER & JOHN THOMAS, PRINCIPLES OF PATENT LAW 4-1 (2d ed. 2004).

<sup>13</sup> 35 U.S.C. §103(a).

<sup>14</sup> *In re Fischer*, 421 F.3d 1365, 1371 (Fed. Cir. 2005).

invention into the United States.<sup>15</sup> Whoever performs any one of these five acts during the term of the invention's patent, without the patent holder's authorization, is liable for infringement.<sup>16</sup> A patent holder may file a civil action against an alleged infringer in order to enjoin him from further infringing acts (by securing an injunction, also referred to as injunctive relief).<sup>17</sup> The patent statute also provides federal courts with discretion to award damages to the patent holder that are "adequate to compensate for the infringement, but in no event less than a reasonable royalty for the use made of the invention by the infringer."<sup>18</sup> The usual term of patent protection is 20 years from the date the patent application is filed.<sup>19</sup> At the end of that period, others may use the invention without regard to the expired patent.

Because the Patent Act expressly provides that "patents shall have the attributes of personal property,"<sup>20</sup> patent holders may sell their patent rights in a legal transfer called an "assignment."<sup>21</sup> Alternatively, patent holders may grant others a "license" to exercise one of the five statutory patent rights.<sup>22</sup> A license is not a transfer of ownership of the patent, but rather is the patent holder's permission to another entity to use the invention in a limited way, typically in exchange for periodic royalty payments during the term of the patent.<sup>23</sup> A patent holder may grant to a licensee the right to practice the invention through a contract (typically known as a patent licensing agreement). The terms of the licensing agreement, however, may include conditions upon the grant of rights—for example, restricting the licensee from making the invention but allowing that party to sell it.<sup>24</sup> A licensee that performs an act that exceeds the scope of the license (through a violation of the limitations and conditions of the grant of rights) or refuses to comply with the terms of the license agreement (such as by refusing to pay the required royalties) is potentially liable to the patent holder for breach of contract as well as for patent infringement.<sup>25</sup>

The U.S. Court of Appeals for the Federal Circuit (Federal Circuit) is a specialized tribunal established by Congress that has exclusive appellate jurisdiction in patent cases.<sup>26</sup> Parties dissatisfied with the Federal Circuit's rulings may petition the U.S. Supreme Court to review the appellate court's decision. However, the Supreme Court is not required to entertain the appeal; it has discretion to decide whether to grant certiorari to review the case.<sup>27</sup>

Besides seeking legal relief for infringement in the federal courts, U.S. patent holders may also obtain an order from the U.S. International Trade Commission (ITC or Commission) preventing the importation of foreign goods that infringe their rights. The ITC is an independent, nonpartisan, quasi-judicial federal government agency responsible for investigating and arbitrating complaints of violations of Section 337 of the Tariff Act of 1930 (19 U.S.C. §1337),

---

<sup>15</sup> 35 U.S.C. §§154(a)(1), 271(a).

<sup>16</sup> *Id.* §271(a).

<sup>17</sup> *Id.* §283.

<sup>18</sup> *Id.* §284.

<sup>19</sup> *Id.* §154(a)(2).

<sup>20</sup> *Id.* §261.

<sup>21</sup> ROGER SCHECHTER & JOHN THOMAS, *PRINCIPLES OF PATENT LAW* §11-1 (2d ed. 2004).

<sup>22</sup> A patent holder has the right to exclude others from making, using, offering for sale, or selling the invention throughout the United States, or importing the protected invention into the United States. 35 U.S.C. §154(a)(1).

<sup>23</sup> SCHECHTER & THOMAS, *supra* footnote 21, §11-1.

<sup>24</sup> *United States v. General Electric Co.*, 272 U.S. 476, 490 (1926).

<sup>25</sup> JOHN R. THOMAS, *PHARMACEUTICAL PATENT LAW* 427 (BNA Books 2005).

<sup>26</sup> 28 U.S.C. §1295(a)(1).

<sup>27</sup> *Id.* §1254(1).



which prohibits unfair methods of competition or other unfair acts in the importation of products into the United States. Section 337 also prohibits the importation of articles that infringe valid U.S. patents, copyrights, processes, trademarks, or protected design rights. (The majority of unfair competition acts asserted under Section 337 involve allegations of patent infringement.)<sup>28</sup> The ITC has the power to order several forms of prospective injunctive relief, including ordering the U.S. Customs and Border Protection (CBP) to stop imports from entering U.S. borders (an exclusion order), or issuing cease and desist orders that prohibit parties from distributing or selling infringing articles from existing U.S. inventory. However, unlike the federal courts, the ITC lacks the statutory authority to award monetary damages for patent infringement (past or future).

Although issued patents are presumed to be valid, accused infringers may assert in court that a patent is invalid or unenforceable on a number of grounds.<sup>29</sup> The accused infringer could raise this argument as an affirmative defense or counterclaim when sued for patent infringement. A party could also preemptively file a “declaratory judgment action”<sup>30</sup> against a patent owner to challenge a patent’s validity, if there is a case or controversy between them.<sup>31</sup>

However, the constitutionally based “case or controversy” requirement for federal judicial proceedings significantly limits the ability of members of the public to challenge the USPTO’s decision to grant a patent. Unless the patent holder becomes involved in an actual, continuing controversy with another person, that person cannot successfully request that a court determine whether the patent is valid or not. To address this perceived deficiency, Congress established several administrative procedures that are conducted by the USPTO’s Patent Trial and Appeal Board, or PTAB,<sup>32</sup> through which any interested person may challenge the validity of an issued patent. Three trial proceedings comprise the current system of administrative patent challenges: inter partes review (IPR), post-grant review (PGR), and the transitional post-grant review for covered business method patents (CBM). The three proceedings have different rules, timing, and eligibility requirements.<sup>33</sup> The proceedings may result in the confirmation of patentability of the original claims, an amended patent with narrower claims, or a declaration of patent invalidity.<sup>34</sup> A

<sup>28</sup> Colleen V. Chien, *Patently Protectionist*, 50 WILLIAM & MARY L. REV. 63, 70 (2008) (patent cases comprise 85% of the ITC’s Section 337 docket). For more information about Section 337 proceedings, see CRS Report RS22880, *Intellectual Property Rights Protection and Enforcement: Section 337 of the Tariff Act of 1930*, by Shayerah Ilias Akhtar.

<sup>29</sup> 35 U.S.C. §282.

<sup>30</sup> For more on declaratory judgment actions in patent cases, see CRS Report RL34156, *A Nonrepudiating Patent Licensee’s Right To Seek Declaratory Judgment of Invalidity or Noninfringement of the Licensed Patent: MedImmune v. Genentech*, by Brian T. Yeh.

<sup>31</sup> The requirement that an immediate, concrete dispute between the patent owner and another individual arises because the U.S. Constitution vests the federal courts with jurisdiction only where a “case or controversy” exists. U.S. CONST., Art. III, Sec. 2, cl. 1. A charge of patent infringement typically satisfies the “case or controversy” requirement. See *Prasco, LLC v. Medicis Pharm. Corp.*, 537 F.3d 1329 (Fed. Cir. 2008).

<sup>32</sup> The PTAB’s membership consists of the USPTO director, deputy director, the Commissioner for Patents, the Commissioner for Trademarks, and the administrative patent judges. 35 U.S.C. §6(a).

<sup>33</sup> The USPTO provides a helpful chart that compares the major differences between the three administrative trials, in terms of (1) who may file a petition with the USPTO to institute the review; (2) when such a petition is allowed; (3) the estoppel provisions applicable to the review (to prevent individuals from making repetitive arguments during later proceedings—either in federal court, the ITC, or in a USPTO administrative proceeding); (4) standards to trigger the review; (5) the standard to prove invalidity; (6) time limits for completing the review; and (7) the basis for challenging validity of the patent, available at [http://beta.uspto.gov/sites/default/files/ip/boards/bpai/aia\\_trial\\_comparison\\_chart.pptx](http://beta.uspto.gov/sites/default/files/ip/boards/bpai/aia_trial_comparison_chart.pptx).

<sup>34</sup> 35 U.S.C. §§318(b); 328(b).



party dissatisfied with the PTAB's final written decision in an IPR, PGR, or CBM review may appeal directly to the Federal Circuit.

## Patent Assertion Entities<sup>35</sup>

“Patent assertion entities” are people or companies that do not develop, manufacture, or sell any product covered by the patents they own. The business model of a patent assertion entity (PAE) instead focuses on buying and asserting patents against companies that have already begun using and developing the patent, often without knowledge of the PAE's ownership of the patent.<sup>36</sup> PAEs emerged alongside the burgeoning tech industry around the turn of the 21<sup>st</sup> century and gained notoriety with lawsuits claiming exclusive ownership of such ubiquitous technologies as wireless email, digital video streaming, and the interactive web.<sup>37</sup> The vast majority of lawsuits brought by PAEs end in settlements because litigation is risky, costly, and disruptive for defendants, and PAEs often offer to settle for amounts well below litigation costs to make the business decision to settle an obvious one.<sup>38</sup> PAEs are frequently referred to as “patent trolls,” after the villains of folklore known to lie in wait under bridges they did not build, then emerge from the smog to demand tolls from unsuspecting travelers.<sup>39</sup> The term “troll” is controversial because it is both pejorative and ambiguous, often used imprecisely for any opportunistic or unpopular patent holder.<sup>40</sup> Instead, PAEs describe themselves as critical intermediaries. Some claim to offer “department stores” for patents, providing one-stop shopping for licensing and purchase.<sup>41</sup> Others suggest they serve key functions by enabling individual inventors to earn returns despite lacking the resources to enforce or commercialize their patents themselves.<sup>42</sup>

However, while PAEs may be considered a type of “non-practicing entity” (NPE), other NPEs can serve similar intermediary functions without engaging in “trolling” tactics.<sup>43</sup> PAEs are alleged to be one-of-a-kind in that they are said to speculate on patents—they bet on how much more a patent will be worth in the future, when it is asserted, and focus on high-risk high-yield

<sup>35</sup> For comprehensive background information on these entities, see CRS Report R42668, *An Overview of the “Patent Trolls” Debate*, by Brian T. Yeh.

<sup>36</sup> FEDERAL TRADE COMMISSION, *THE EVOLVING IP MARKETPLACE: ALIGNING PATENT NOTICE AND REMEDIES WITH COMPETITION* 67-68 (2011).

<sup>37</sup> See Gerard N. Magliocca, *Blackberries and Barnyards: Patent Trolls and the Perils of Innovation*, 82 NOTRE DAME L. REV. 1809 (2007).

<sup>38</sup> John R. Allison, Mark A. Lemley & Joshua Walker, *Patent Quality and Settlement Among Repeat Patent Litigants*, 99 GEO. L.J. 677, 694 (2011).

<sup>39</sup> The term was coined at Intel in 2001 as a pithy label for litigants asserting patents that they owned but did not practice and which they typically acquired. An Intel Corporation vice president had been sued after referring to such litigants as “patent extortionists.” See Joff Wild, *The Real Inventors of the Term “Patent Troll” Revealed*, IAM MAGAZINE, August 22, 2008, <http://iam-magazine.com/blog/detail.aspx?g=cf2afd3-c24e-42e5-aa68-a4b4e7524177>.

<sup>40</sup> See, e.g., Ronald S. Katz et al., *Patent Trolls: A Selective Etymology*, IP LAW 360, March 20, 2008, [http://manatt.com/uploadedFiles/News\\_and\\_Events/Articles\\_By\\_Us/patentroll.pdf](http://manatt.com/uploadedFiles/News_and_Events/Articles_By_Us/patentroll.pdf); see also Jenna Greene, *Trolls? Patent Director Says the Term Isn't Helpful*, NAT'L LAW JOURNAL, January 22, 2015 (quoting USPTO Director Michelle Lee: “I don't find the term [patent troll] helpful. It means different things to different people. We need to focus on behavior.”).

<sup>41</sup> Nathan Myhrvold, *The Big Idea: Funding Eureka!*, HARV. BUS. REV. 44 (2010).

<sup>42</sup> *Id.* at 48–49; Sannu K. Shrestha, *Trolls or Market-Maker? An Empirical Analysis of Nonpracticing Entities*, 110 COLUM. L. REV. 114, 126–30 (2010); FTC Report, *supra* note 36, at 64, 68.

<sup>43</sup> See, e.g., James Bessen et. al., *The Private and Social Costs of Patent Trolls*, REGULATION 26, 34 (2006); Elizabeth D. Ferrill, *Patent Investment Trusts: Let's Build a PIT to Catch the Patent Trolls*, 6 N.C. J.L. & TECH. 367, 371–374 (2005).

acquisitions.<sup>44</sup> The Federal Trade Commission has explained that while other NPEs transfer technologies that they or their clients invented and developed so that licensees can benefit from not having to develop them in-house, PAEs transfer nothing but a legal right not to be sued for using a technology that the licensee may have already invested in developing on its own, without help from the PAE or its patents.<sup>45</sup> PAEs also diverge from other NPEs that *enforce* patents because they focus on acquiring patents outright and asserting them on their own behalf, as opposed to providing services and collecting fees or a slice of the litigation award.<sup>46</sup>

Critics of PAEs argue that they extort the patent system through litigation by extracting licensing fees or damage awards from companies that cannot afford the cost of litigation. Critics also argue that “patent trolling” deters innovation and discourages companies from seeking patents, and thus delivering new products to the market.<sup>47</sup> According to the White House:

PAE activities hurt firms of all sizes. Although many significant settlements are from large companies, the majority of PAE suits target small and inventor-driven companies. In addition, PAEs are increasingly targeting end users of products, including many small businesses.<sup>48</sup>

However, defenders of PAEs argue that they actually promote invention by increasing the liquidity and managing the risk of investments in applied research and invention, as well as by compensating small inventors.<sup>49</sup> By enlivening a secondary<sup>50</sup> market for patents, PAEs provide an exit option and/or extra revenue stream for a variety of patentees. They absorb and manage the high risk by spreading it across large portfolios of patents and extracting value out of otherwise low-value or dormant patents. Patentees who do not or cannot commercialize in the “primary” market for technology<sup>51</sup> might recoup their costs and perhaps see some returns by selling their patents to PAEs and retaining a cut of future royalties. PAEs suggest this function is especially essential for small inventors and NPEs that would otherwise have a hard time getting any value from their inventions.

## Legislation in the 114<sup>th</sup> Congress

The remainder of this report discusses and analyzes the key provisions of legislative proposals that have been introduced in the 114<sup>th</sup> Congress related to patent litigation abuse. The subject matter of the patent law reforms is presented below in no particular order.

<sup>44</sup> Bessen et. al, *supra* note 43, at 34.

<sup>45</sup> FTC Report, *supra* note 36, at 40 n. 43.

<sup>46</sup> Ferrill, *supra* note 43, at 371–374.

<sup>47</sup> See, e.g., Bessen et. al, *supra* note 43, at 31-35.

<sup>48</sup> EXECUTIVE OFFICE OF THE PRESIDENT, PATENT ASSERTION AND U.S. INNOVATION 1 (June 2013), at [https://www.whitehouse.gov/sites/default/files/docs/patent\\_report.pdf](https://www.whitehouse.gov/sites/default/files/docs/patent_report.pdf).

<sup>49</sup> See, e.g., Ron Epstein, *Debunking the ‘Patent Troll’ Myth*, BLOOMBERG BUSINESSWEEK, August 15, 2011, available at <http://www.businessweek.com/stories/2010-02-01/debunking-the-patent-troll-mythbusinessweek-business-news-stock-market-and-financial-advice>.

<sup>50</sup> In the *primary* market for *technology*, revenue and returns on investment come from commercializing the patented technology and exploiting exclusive rights to use it in the marketplace. In the *secondary* market for *patents*, revenue comes from licensing fees. PAEs sell or license their patents “as assets whose values are based on the amount of licensing fees that can be extracted from operating companies already using and marketing the technology.” See FTC Report, *supra* note 36, at 60.

<sup>51</sup> Smaller inventors may lack the resources or know-how to commercialize, and it will often be inefficient for them to try. Other patents may not become valuable for years or require further capital and sunk costs.

## Heightened Pleading Requirements

The U.S. Supreme Court recently adopted a rule, which went into effect on December 1, 2015, that abolished Federal Rules of Civil Procedure’s Form 18.<sup>52</sup> According to Form 18, a complaint for patent infringement<sup>53</sup> needed to include four statements that assert jurisdiction, patent ownership, patent infringement by the defendant, and a demand for relief.<sup>54</sup> Plaintiffs typically relied upon the Federal Rules of Civil Procedure’s Form 18 to structure their patent infringement complaint. Generally, the Federal Circuit had applied the “notice pleading standard” to patent infringement pleadings for the purpose of a motion to dismiss for failure to state a claim (a typical method by which a defendant may attempt to have a case dismissed at the beginning of the case). Under this standard, a court finds that the patent pleading statements contain sufficient particularity to survive a motion to dismiss for failure to state a claim if they notify parties of the general issues of the case. In *K-Tech Telecommunications v. Time Warner Cable*, the Federal Circuit held that the information required by the Federal Rules of Civil Procedure’s Form 18 is sufficient for pleading a patent infringement claim as the form states a plausible claim and places the alleged infringer on notice.<sup>55</sup> Additionally, the Federal Circuit in *McZeal v. Sprint Nextel Corporation* found that a party does not need to describe the relationship between each element of the claim and the infringing device in a patent infringement complaint.<sup>56</sup> According to the court, specific information such as this “is something to be determined through discovery.”<sup>57</sup>

Under the Supreme Court’s recent changes to the federal rules, patent plaintiffs may no longer rely on the standard outlined in Form 18 but will likely need to comply with the higher pleading standard under *Ashcroft v. Iqbal*<sup>58</sup> and *Bell Atlantic Corp. v. Twombly*.<sup>59</sup> In *Twombly* and *Iqbal*, the Supreme Court established that federal courts must evaluate the “plausibility of claims” made at the pleading stage when determining whether a civil complaint should survive a motion to dismiss for failure to state a claim.<sup>60</sup> Therefore, under the *Twombly/Iqbal* standard, a complaint must contain enough factual allegations to state a claim that is plausible on its face. However, prior to the Supreme Court’s recent changes, courts have generally found that *Iqbal* and *Twombly* do not apply to patent litigation pleadings because of Form 18 and its inherent notice pleading standard. The Federal Circuit held in the 2012 case *In re Bill of Lading Transmission and Processing System Patent Litigation* that a patent plaintiff needs only to follow the requirements in Form 18 to survive a motion to dismiss for failure to state a claim.<sup>61</sup> The court stated that “to the extent the parties argue that *Twombly* and its progeny conflict with the Forms and create different pleadings requirements, the Forms control.”<sup>62</sup> Without Form 18, however, patent plaintiffs will likely need to conform their patent pleadings to the higher *Twombly/Iqbal* standard.

<sup>52</sup> U.S. Supreme Court Order, April 2015.

<sup>53</sup> As previously discussed, patent infringement is the unauthorized making, using, offering for sale, selling, and importing of a patented invention. 35 U.S.C. §271.

<sup>54</sup> Fed. R. Civ. P. Form 18.

<sup>55</sup> *K-Tech Telecommunications v. Time Warner Cable*, 714 F.3d 1278 (Fed. Cir. 2013).

<sup>56</sup> *McZeal v. Sprint Nextel Corp.*, 501 F.3d 1354, 1358 (Fed. Cir. 2007).

<sup>57</sup> *Id.*

<sup>58</sup> *Ashcroft v. Iqbal*, 556 U.S. 662 (2009).

<sup>59</sup> *Bell Atl. Corp. v. Twombly*, 550 U.S. 544 (2007).

<sup>60</sup> *Iqbal*, 556 U.S. at 678; *Twombly*, 550 U.S. at 556.

<sup>61</sup> *In re Bill of Lading Transmission and Process System Patent Litigation*, 681 F.3d 1323, 1334 (Fed. Cir. 2012).

<sup>62</sup> *Id.*

The Innovation Act, H.R. 9, proposes additional heightened initial pleading requirements for an infringement claim, as compared to the current requirements under the Federal Rules of Civil Procedure’s Form 18. Under these new requirements, a party alleging infringement in a complaint must include specific details regarding the following:

- each patent allegedly infringed;
- all claims necessary to produce the identification of each process, machine, manufacture, or composition of matter (“accused instrumentality”) that is alleged to infringe any claim of each patent identified above;<sup>63</sup>
- for each accused instrumentality alleged to infringe a claim, an identification with particularity (if known) of the name or model number of each accused instrumentality or a description of each accused instrumentality;
- for each accused instrumentality, a clear and concise statement of how it infringes each claim of each patent;
- for each claim of indirect infringement, the acts of the alleged indirect infringer that contribute to, or are inducing, a direct infringement;
- the authority of the party alleging infringement to assert each patent and the grounds for the court’s jurisdiction; and
- each complaint filed that asserts any of the same patents<sup>64</sup>

Like the Innovation Act, the Senate’s PATENT Act also proposes heightened pleading requirements, including such details as

- the identification of each patent allegedly infringed;
- the identification of each claim of each patent that is allegedly infringed;
- the identification (including the name, model number, or description) of the accused instrumentality that has allegedly infringed the patent;
- a description of how the accused instrumentality is allegedly infringing specific elements of the claim; and
- a description of the acts of the alleged infringer that allegedly contributed to or induced the direct infringement, for claims of indirect infringement.<sup>65</sup>

The PATENT Act would not require such details in the initial pleading as the authority of the party alleging infringement to assert each patent and the principal business of the party alleging infringement, as outlined in the House’s Innovation Act. Instead, the Senate bill would require the patentee to disclose specific information to the court and each adverse party no later than 14 days after the filing of the pleading.<sup>66</sup> These disclosure requirements would cover the identity of the patent assignee(s), the right to enforce the patent at issue, any ultimate parent entity, and entities

---

<sup>63</sup> As originally introduced, H.R. 9 would have required “[a]n identification of each claim of each patent ... that is allegedly infringed” (which is also the same information required by the PATENT Act). However, the Manager’s Amendment to the Innovation Act that was approved by the House Judiciary Committee on June 11, 2015, replaces that language with the text described above, thereby lowering the standard of this particular pleading requirement.

<sup>64</sup> H.R. 9, §3, *adding new* 35 U.S.C. §281A.

<sup>65</sup> S. 1137, §3, *adding new* 35 U.S.C. §281A.

<sup>66</sup> *Id.*, *adding new* 35 U.S.C. §281B.

that would have a particular financial interest in the patent at issue.<sup>67</sup> Both the Innovation Act and PATENT Act would also explicitly eliminate the Federal Rules of Civil Procedure’s Form 18.<sup>68</sup>

Both the PATENT Act and the Innovation Act provide that if the information is not readily accessible, then the party may generally describe the information with an explanation of why such undisclosed information was not readily accessible.<sup>69</sup> Similarly, both bills also exempt from the proposed heightened pleading requirements any civil action that includes a claim for relief arising under Section 271(e)(2) of the current Patent Act relating to certain drug claims.<sup>70</sup> Commentators have linked “patent trolls” together with the current patent pleading requirements for a patent infringement claim.<sup>71</sup> They have argued that the minimal information required in a patent infringement complaint encourages PAEs to initiate “frivolous” lawsuits that otherwise would not survive the initial pleading state under a more stringent standard. Proponents of these pleadings changes state that such heightened pleading requirements would force a plaintiff to consider the alleged infringement instrumentality more carefully and decide whether infringement has occurred before filing the suit.<sup>72</sup> Supporters of heightened pleading requirements also argue that “not providing the necessary information at the beginning of a case in the complaint slows down the litigation and makes it inefficient and expensive for both parties.”<sup>73</sup> Additionally, these proponents assert that heightened pleadings standards would not impose a greater burden on the plaintiff, who would develop a good-faith case, and providing such information at the early stages of litigation would improve efficiency and costs.<sup>74</sup> However, some commentators believe that the heightened pleading requirements would render patent enforcement impractical. According to these opponents, the plaintiff may not have the information available at this stage of litigation, as the discovery process typically reveals the information necessary to build a successful infringement claim.<sup>75</sup>

## Limits on Discovery and Cost-Shifting

The Federal Rules of Civil Procedure permit discovery<sup>76</sup> into any unprivileged matter that is relevant to the claim or defense of any party.<sup>77</sup> This broad definition leads to costly discovery in

<sup>67</sup> *Id.*

<sup>68</sup> H.R. 9, §6; S. 1137, §3. The Supreme Court’s order abolishing Form 18 went into effect on December 1, 2015 absent congressional action.

<sup>69</sup> H.R. 9, §3, *adding new* 35 U.S.C. §281A; S. 1137, §3, *adding new* 35 U.S.C. §281A.

<sup>70</sup> The Innovation Act and the PATENT Act provide an exception to this disclosure requirement for civil actions that include a specific cause of action for patent infringement involving pharmaceutical drugs. The particular cause of action, established by the Hatch-Waxman Act and codified in 35 U.S.C. §271(e)(2), allows a brand-name drug company to enforce its patents against a potential generic competitor at such time that the generic firm files an application (a so-called Abbreviated New Drug Application (ANDA)) with the Food and Drug Administration, seeking marketing approval. For more information on this provision, *see* CRS Report R42354, *Patent Infringement and Experimental Use Under the Hatch-Waxman Act: Current Issues*, by John R. Thomas.

<sup>71</sup> *See, e.g.*, Patent Progress, *Common Sense Solutions to the Patent Control Problem*, at <http://www.patentprogress.org/patent-troll-reform/common-sense-solutions-to-the-patent-troll-problem/>.

<sup>72</sup> H.Rept. 113-279, at 23.

<sup>73</sup> *Id.*

<sup>74</sup> *Id.*

<sup>75</sup> *See* Edward R. Ergenzinger and Andrew R. Shores, “Here We Go Again: The Next Round of Legislative Patent Law Reform,” at <http://www.wardandsmith.com/articles/the-next-round-of-legislative-patent-law-reform>.

<sup>76</sup> Discovery is the process to gather information in preparation for trial.

<sup>77</sup> *See* Fed. R. Civ. P. 26.

patent litigation.<sup>78</sup> During the discovery process, the court may decide to hold a “Markman hearing,”<sup>79</sup> during which a judge examines evidence concerning the parties’ disputes over the meaning and language of a patent claim that defines the boundaries of the invention. (Also referred to as “claim construction,” or the interpretation of a patent’s claims, this process largely determines the scope of the patent owner’s proprietary rights.) For these hearings, courts must consider volumes of evidence produced during discovery relating to many different aspects of claim construction including evidence regarding the definition, meaning, scope, and pertinent art of the claim.<sup>80</sup>

The Innovation Act (as reported) would postpone discovery if the defendant makes a motion to (1) sever a claim or drop a party for misjoinder; (2) transfer the action to another venue; or (3) dismiss the action.<sup>81</sup> Such motion must be filed within 90 days after service of the complaint and must include a declaration or other evidence in support of the motion. There are four exceptions to this stay of discovery provision:

1. the court may allow such discovery that the court deems is necessary to decide the motion to sever, drop a party, dismiss, or transfer the action;
2. the provision does not apply to an action in which the patent holder seeks a preliminary injunction to prevent harm arising from the manufacture, use, sale, or importation of an allegedly infringing product that competes with a product made or sold by the patent holder;
3. parties may consent to voluntary exclusion from these proposed limitations on discovery; and
4. the provision does not apply to any civil action that includes a claim for relief arising under 35 U.S.C. Section 271(e)(2) relating to certain drug claims.<sup>82</sup>

Like the Innovation Act (as reported), the Senate’s PATENT Act would require a court to stay discovery pending the resolution of preliminary motions (which must be filed prior to the first responsive pleading), including the motion to dismiss, the motion to transfer venue, and the motion to sever accused infringers.<sup>83</sup> The bill would provide a court with the discretion to allow limited discovery to resolve these motions or a motion for a preliminary injunction or to preserve evidence or otherwise prevent specific prejudice to a party, if the court would find that additional discovery is necessary.<sup>84</sup> Similar to the Innovation Act, the PATENT Act would also grant parties with the opportunity to exclude themselves voluntarily from these proposed limitations.

Supporters of these proposed limitations on discovery note that the technical nature and complexity of patent litigation inherently leads to the extensive document discovery, and

<sup>78</sup> See Chief Judge Randall R. Rader, *The State of Patent Litigation*, Eastern District of Texas Bar Association Judicial Conference, September 27, 2011.

<sup>79</sup> This type of hearing developed as the result of the U.S. Supreme Court decision in *Markman v. Westview Instruments, Inc.*, 517 U.S. 370 (1996).

<sup>80</sup> See *Phillips v. AWH Corp.*, 415 F.3d 1303 (Fed. Cir. 2005).

<sup>81</sup> H.R. 9 (as reported), §3(d), *adding new* 35 U.S.C. §281B(a). As introduced, the Innovation Act would have required that hearings relating to patent claim construction occur prior to significant fact discovery, as the bill would have limited discovery “to information necessary for the court to determine the meaning of the terms used in the patent claim.” H.R. 9 (as introduced), §3, *adding new* 35 U.S.C. §299A. In addition, the Innovation Act (as introduced) would have granted courts with the discretion to permit discovery “in special circumstances” to prevent manifest injustice. *Id.*

<sup>82</sup> H.R. 9 (as reported), §3(d), *adding new* 35 U.S.C. §281B(d).

<sup>83</sup> S. 1137, §4, *adding new* 35 U.S.C. §299B.

<sup>84</sup> *Id.*



correspondingly encourages frequent settlements to avoid this high cost.<sup>85</sup> These supporters have stated that the propensity towards settlements in patent litigation encourages PAEs to file infringement suits. Critics of these discovery limitations have raised concerns that the discovery limitation provision may cause “patent litigation in the overwhelming majority of patent cases [to] incur significant across-the-board delays and increased expense for all parties.”<sup>86</sup> Others have argued that the discovery stay provision could be subject to abuse; for example, a “defendant could ... invoke a stay of discovery by moving to transfer venue or to sever, even though the merits of a venue or severance motion have no bearing whatsoever on whether or not the plaintiff will ultimately be allowed discovery.”<sup>87</sup>

## Transparency of Patent Ownership<sup>88</sup>

Under current law, within a month after the filing of a civil action involving a patent, the clerks of the federal courts must provide written notice of the action to the USPTO director that describes the names and addresses of the parties, the name of the inventor, and the number of the patent upon which the action is based.<sup>89</sup> The USPTO director is then required to enter this information in the file of that patent.

Section 4 of the Innovation Act would amend this section of the Patent Act to impose specific disclosure requirements upon plaintiffs upon the filing of an initial complaint for patent infringement. (Similar to the exemption for the new pleading requirements, the Innovation Act’s patent ownership disclosure requirement would not apply to any civil action that includes a cause of action for patent infringement under 35 U.S.C. §271(e)(2).)<sup>90</sup> Upon the filing of an initial complaint for patent infringement, plaintiffs would be required to disclose to the USPTO, the court, and all adverse parties the following information relating to entities that own or have a financial interest in the patent:

1. the assignee(s) of the patent(s) involved in the case;
2. any entity with a right to sublicense or enforce the patent(s) at issue;
3. any entity, other than the plaintiff, that the plaintiff knows to have a financial interest<sup>91</sup> in the patent(s) at issue or in the plaintiff;
4. the ultimate parent entity<sup>92</sup> of any assignee, or the entities identified in #2 and #3 above;

<sup>85</sup> H.Rept. 113-279, at 9.

<sup>86</sup> *The Impact of Abusive Patent Litigation Practices on the American Economy: Hearing Before the Senate Judiciary Comm.*, 114<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2015) (Statement of Hans Sauer, Deputy General Counsel for Intellectual Property, Biotechnology Industry Organization).

<sup>87</sup> *Innovation Alliance Priority Positions on S. 1137, the Senate Protecting American Talent and Entrepreneurship (PATENT) Act*, May 6, 2015, at <http://innovationalliance.net/from-the-alliance/innovation-alliance-priority-positions-s-1137-senate-protecting-american-talent-entrepreneurship-patent-act/>.

<sup>88</sup> This topic is often referred to as the disclosure of the “real party-in-interest.”

<sup>89</sup> 35 U.S.C. §290.

<sup>90</sup> H.R. 9, §4(a)(3), *adding new* 35 U.S.C. §290(b)(2).

<sup>91</sup> The Innovation Act defines “financial interest” to mean (1) with regard to a patent, the right of a person to receive proceeds related to the assertion of the patent(s), and (2) with regard to the plaintiff, direct or indirect ownership or control by a person of more than 5% of such plaintiff. H.R. 9, §4(a)(3), *adding new* 35 U.S.C. §290(e)(1). However, the definition expressly excludes anyone who owns shares or other interests in a mutual or common investment fund (unless the person participates in the management of such fund) and also excludes the proprietary interest of a policyholder in a mutual insurance company or of a depositor in a mutual savings association, unless the outcome of the civil action could substantially affect the value of that proprietary interest.



5. a clear and concise description of the principal business, if any, of the party alleging infringement;<sup>93</sup>
6. a list of each complaint filed, of which the party alleging infringement has knowledge, that asserts or asserted any of the patents identified above;<sup>94</sup>
7. for each patent identified, a statement as to whether the patent is subject to certain licensing requirements (imposed by the federal government, a foreign government, or by a standards development organization).<sup>95</sup>

Section 4 of the Innovation Act would require the plaintiff to notify the USPTO of any changes in the identity of the assignee of the patent or the entities described above, within 90 days of such change.<sup>96</sup> Failure to comply with this ongoing duty of disclosure would result in the plaintiff being barred from recovering either enhanced damages or reasonable fees and other expenses incurred in connection with the infringement lawsuit (with respect to infringing activities occurring during the period of noncompliance), “unless the denial of such damages or fees would be manifestly unjust.”<sup>97</sup> In addition, the Innovation Act directs a court to award to a prevailing party accused of infringement any reasonable fees and other expenses that the party incurred to uncover the updated information about the assignee or entities, “unless such sanctions would be unjust.”<sup>98</sup>

Section 4 of the Innovation Act grants the USPTO director the power to issue regulations to establish a registration fee in order to recover the cost of administering the “disclosure of interests” requirement, which includes the costs to facilitate collection and maintenance of the information submitted by plaintiffs and “to ensure the timely disclosure of such information to the public.”<sup>99</sup>

According to the sponsors of the Innovation Act, the amendments made by Section 4 “will ensure that patent trolls cannot hide behind a web of shell companies to avoid accountability for bringing frivolous litigation.”<sup>100</sup> However, a critic of this provision argued that it would be “needlessly burdensome” and that the required disclosure “could lead to the revelation of confidential financial and licensing agreements”;<sup>101</sup> furthermore, he noted that if such information is relevant to the litigation, “it is readily discoverable under current rules, with appropriate protective orders to maintain needed confidentiality.”<sup>102</sup>

---

(...continued)

<sup>92</sup> The Innovation Act defines “ultimate parent entity” by reference to 16 C.F.R. §801.1(a)(3), which provides that the term “means an entity which is not controlled by any other entity.” H.R. 9, §4(a)(3), *adding new* 35 U.S.C. §290(e)(3).

<sup>93</sup> Additional required information added by the Manager’s Amendment to the Innovation Act, which was approved by the House Judiciary Committee. *See* H.R. 9 (as reported), §4(a)(3), *adding new* 35 U.S.C. §290(b)(1)(E).

<sup>94</sup> *Id.*, *adding new* 35 U.S.C. §290(b)(1)(F).

<sup>95</sup> *Id.*, *adding new* 35 U.S.C. §290(b)(1)(G).

<sup>96</sup> H.R. 9, §4(a)(3), *adding new* 35 U.S.C. §290(d)(1).

<sup>97</sup> *Id.*, *adding new* 35 U.S.C. §290(d)(2)(A).

<sup>98</sup> *Id.*, *adding new* 35 U.S.C. §290(d)(2)(B).

<sup>99</sup> *Id.* §4(c).

<sup>100</sup> *Press Release: Goodlatte, Defazio, Issa, Nadler, Smith, Lofgren, Eshoo Introduce Patent Litigation Reform Bill*, February 5, 2015, available at <http://judiciary.house.gov/index.cfm/2015/2/goodlatte-defazio-issa-nadler-smith-lofgren-eshoo-introduce-patent-litigation-reform-bill>.

<sup>101</sup> Howard Klein, *Patent Law Reform—Proceed with Caution*, Law360.com, March 9, 2015, at <http://www.law360.com/articles/626618/patent-law-reform-proceed-with-caution>.

<sup>102</sup> *Id.*

The PATENT Act would require similar initial disclosures by a patentee in a patent infringement lawsuit as the Innovation Act.<sup>103</sup> Within 14 days of the patentee filing the pleading, the patentee would be required to notify the court and each adverse party of the following information:

1. The identity of each:
  - a. assignee of the patent(s) at issue, and any “ultimate parent entity”<sup>104</sup> thereof;
  - b. entity with a right to sublicense to unaffiliated entities or to enforce the patent(s) at issue, and any ultimate parent entity thereof;
  - c. any other entity that the patentee knows to have a financial interest<sup>105</sup> in the patent(s) at issue, or in the patentee (and any ultimate parent entity thereof); and
2. For each patent that the patentee alleges to be infringed:
  - a. a list of other complaints filed by the patentee in the three years before the filing of the action, as well as any other complaints filed in the United States (not by the patentee but that the patentee was aware of) that asserted the patent during the same three-year period;
  - b. a statement as to whether the patent is subject to certain licensing requirements (imposed by the federal government or by a standards development organization).<sup>106</sup>

The PATENT Act would allow the patentee to file such information under seal if the patentee considers the information to be confidential (such as the home addresses of any individuals);<sup>107</sup> the Innovation Act does not contain a similar provision.

Within a month of the disclosure of the information listed above, the patentee would be required to file the information described in #1 above with the USPTO.<sup>108</sup> However, unlike the Innovation Act, the PATENT Act does not appear to place upon the patentee an ongoing duty of disclosure of such information to the USPTO.

In addition, Section 10 of the PATENT Act would require that an assignment of all substantial rights in any issued patent (and the name of the assignee and the ultimate parent entity of the assignee) be recorded in the USPTO within the following time periods:

1. no later than the date on which the patent is issued; and
2. when any subsequent assignment is made that results in a change to the ultimate parent entity
  - a. no later than three months after such assignment is made; or,

---

<sup>103</sup> S. 1137, §3(b)(1), *adding new* 35 U.S.C. §281B(b). However, unlike the Innovation Act, the PATENT Act would NOT create an exception to the patent ownership disclosure requirement for a civil action that includes a cause of action for patent infringement under 35 U.S.C. §271(e)(2).

<sup>104</sup> The PATENT Act uses the same definition for “ultimate parent entity” as the Innovation Act.

<sup>105</sup> The PATENT Act defines the term “financial interest” in a similar fashion to the Innovation Act, except that S. 1137 would, with regard to the patentee, apply the term to persons who have “direct or indirect ownership or control” of more than 20% of the patentee (compared to the Innovation Act’s 5%).

<sup>106</sup> For more information about the promise of members of standard-setting organizations to license certain patented inventions to others on “fair, reasonable, and nondiscriminatory (FRAND) terms,” see CRS Report R42705, *Availability of Injunctive Relief for Standard-Essential Patent Holders*, by Brian T. Yeh.

<sup>107</sup> *Id.*, *adding new* 35 U.S.C. §281B(e).

<sup>108</sup> *Id.* §3(b)(1), *adding new* 35 U.S.C. §281B(d).

- b. in the case of an assignment made as part of a corporate acquisition, not later than six months after the closing date of such acquisition.<sup>109</sup>

The PATENT Act provides similar consequences as the Innovation Act for failure to comply with the duty to disclose this information to the USPTO: that is, the party asserting infringement of a patent would be denied the right to receive either enhanced damages or reasonable fees and other expenses incurred in connection with the infringement lawsuit (with respect to infringing activities occurring during the period of noncompliance).<sup>110</sup> Like the Innovation Act, the PATENT Act would also require a court to award to a prevailing accused infringer reasonable attorney fees and expenses incurred to discover the identity of any undisclosed entity that was required to be disclosed.<sup>111</sup> Under the PATENT Act, the USPTO Director would be given the same authority granted by the Innovation Act to establish fees to administer the process of collecting and maintaining the submitted assignment information.<sup>112</sup>

## Stays of Litigation Brought Against Infringing Customers

Under the Patent Act, anyone who “makes, *uses*, offers to sell, or sells any patented invention”<sup>113</sup> is potentially liable for patent infringement if such actions occur without the authority of the patent holder. Thus, the patent holder has the right to bring a lawsuit against not only the manufacturer or seller of products that incorporate allegedly infringing components, but also the customers who purchase and use those products.<sup>114</sup> Over the past few years, businesses (including restaurants, retailers, and grocery stores) and individuals increasingly have faced charges of patent infringement for their use of certain equipment that contain technologies such as Wi-Fi, PDF scanning, email, and vehicle tracking.<sup>115</sup> A witness at a congressional hearing in 2013 described the situation as follows:

Another patent litigation practice that has been sharply criticized is the institution of suits against large numbers of assemblers, distributors or retailers rather than the original manufacturer or provider of the component or product alleged to infringe. This tactic takes advantage of the fact that such suits threaten defendants with the disruption of aspects of their businesses that are at best tangentially related to the invention which is the subject of the patent, and that each individual defendant has less motivation to litigate the issue to final conclusion than the manufacturer of the product at issue. The result can be to collect enormous sums as the result of a very large number of small settlements whose cumulative value far exceeds the amount that could have been recovered from the original manufacturer.<sup>116</sup>

<sup>109</sup> *Id.* §10(a), adding new 35 U.S.C. §261(A)(b), (c).

<sup>110</sup> *Id.*, adding new 35 U.S.C. §261(A)(d).

<sup>111</sup> *Id.*

<sup>112</sup> *Id.* §10(b).

<sup>113</sup> 35 U.S.C. §271(a) (emphasis added).

<sup>114</sup> *See* Aro Mfg. Co., Inc. v. Convertible Top Replacement Co., Inc., 377 U.S. 476, 484 (1964) (explaining that “it has often and clearly been held that unauthorized use, without more, constitutes infringement.”).

<sup>115</sup> *See* Colleen V. Chien & Edward Reines, *Why Technology Customers Are Being Sued en Masse for Patent Infringement & What Can Be Done* (Santa Clara Univ. Sch. of L. Legal Studies Research Papers Series, Working Paper No. 20-13, 2013), available at [http://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=2318666](http://papers.ssrn.com/sol3/papers.cfm?abstract_id=2318666).

<sup>116</sup> *Abusive Patent Litigation: The Impact on American Innovation & Jobs, and Potential Solutions: Hearing Before the House Judiciary Comm., Subcomm. on Courts, Intellectual Property, and the Internet*, 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013) (Statement of Philip S. Johnson, Chief Intellectual Property Counsel, Johnson & Johnson, on behalf of the 21<sup>st</sup> Century Coalition for Patent Reform), at 7, available at [http://judiciary.house.gov/\\_files/hearings/113th/03142013\\_2/](http://judiciary.house.gov/_files/hearings/113th/03142013_2/) (continued...)

The judicially created response to such customer lawsuits is the so-called “customer suit exception” doctrine, which allows courts to prioritize litigation against or brought by the manufacturer of infringing goods over a lawsuit by the patent owner against customers of the manufacturer in the interest of efficiency and judicial economy.<sup>117</sup> The doctrine permits a court to stay an earlier-filed action against a customer involving an infringement product pending the outcome of a later-filed declaratory judgment action brought by the manufacturer of the accused product. As explained by the First Circuit Court of Appeals (prior to the creation of the Federal Circuit), “At the root of the preference for a manufacturer’s declaratory judgment action is the recognition that, in reality, the manufacturer is the true defendant in the customer suit.... [I]t is a simple fact of life that a manufacturer must protect its customers, either as a matter of contract, or good business, or in order to avoid the damaging impact of an adverse ruling against its products.”<sup>118</sup> However, the doctrine “has long existed in a state of relative disuse” and the Federal Circuit has affirmed its application in only one case in the last three decades.<sup>119</sup>

Section 5 of the Innovation Act would codify a modified version of the customer suit exception by amending the Patent Act<sup>120</sup> to require a court to suspend or postpone litigation against a customer of a product or process that contains allegedly infringing technologies, if several requirements are satisfied:<sup>121</sup>

1. the manufacturer is a party to the civil action or a separate action involving the same patent(s);
2. the customer agrees to be bound by the decisions of the court in the action involving the manufacturer, with respect to any issues that the customer and manufacturer have in common; and
3. the customer requests the court to stay the action no later than the later of (a) 120 days after the date on which the first pleading in the action is served (if such pleading specifically identifies the product or process that is the source of the customer’s alleged infringement of the patent, and the pleading specifically explains how the product or process is alleged to infringe the patent), or (b) the date on which the first scheduling order in the case is entered.

The Innovation Act provides two limited exceptions to the manufacturer and customer’s entitlement to a stay: (1) if the action involving the manufacturer will not resolve a major issue in the suit against the customer; or (2) if the stay unreasonably prejudices and would be manifestly unjust to the party seeking to lift the stay.<sup>122</sup> In addition, like the exemption for the new pleading

(...continued)

Johnson%2003142013.pdf.

<sup>117</sup> *Spread Spectrum Screening LLC v. Eastman Kodak Co.*, 657 F.3d 1349, 1357 (Fed. Cir. 2011).

<sup>118</sup> *Codex Corp. v. Milgo Electronic Corp.*, 553 F.2d 735 (1<sup>st</sup> Cir.), *cert. denied*, 434 U.S. 860 (1977).

<sup>119</sup> Brian J. Love and James C. Yoon, *Expanding Patent Law’s Customer Suit Exception*, 93 B.U. L. REV. 1605, 1614 (October 2013), citing *Katz v. Lear Siegler, Inc.*, 909 F.2d 1459 (Fed. Cir. 1990).

<sup>120</sup> H.R. 9, §5(a), replacing existing 35 U.S.C. §296 that contains an unrelated provision that attempted to make state governments and state institutions liable for monetary damages in a patent infringement lawsuit. This provision that sought to abrogate a state’s Eleventh Amendment sovereign immunity has been invalidated by the Supreme Court in a 1999 decision, *Florida Prepaid v. College Savings Bank*, 527 U.S. 627 (1999). For more information on this issue, see CRS Report RL34593, *Infringement of Intellectual Property Rights and State Sovereign Immunity*, by Brian T. Yeh.

<sup>121</sup> H.R. 9 (as reported), §5(a), *adding revised* 35 U.S.C. §296(b)(1)–(3). As originally introduced, the Innovation Act would have required both the manufacturer of the product and the customer to consent to the stay of the action in writing. H.R. 9 (as introduced), *adding revised* 35 U.S.C. §296(a)(1).

<sup>122</sup> *Id.*, *adding revised* 35 U.S.C. §296(c).

and patent ownership disclosure requirements, the Innovation Act exempts from the customer suit stay provision any action that includes a cause of action for patent infringement under 35 U.S.C. Section 271(e)(2).<sup>123</sup>

Though the stay provision would only postpone, and not terminate, a cause of action against the customer, supporters of the stay provision assert that “in the vast majority of cases, a suit involving the manufacturer will eliminate all potential infringement liability of the customer.”<sup>124</sup>

The Innovation Act (as reported) contains definitions of “covered customer,” “retailer,” and “end user” that limit the applicable scope of the customer stay provision, as follows:

1. A “covered customer” is a retailer or end user who is accused of patent infringement based on sale or use of a product/process alleged to infringe a patent, if the retailer or end user did not materially modify such product/process for their own purposes.
2. An “end user” is a user of a product/process alleged to infringe a patent and also an affiliate of such an end user, but does not include an entity that manufactures (or causes the manufacture of) the product/process.
3. A “retailer” is an entity that generates its revenues mostly through sale of consumer goods or services, or an affiliate of such an entity, but does not include an entity that manufactures (or causes the manufacture of) the product/process alleged to infringe a patent.

The PATENT Act includes a customer stay provision similar to that of the Innovation Act (as reported).<sup>125</sup>

Both the Innovation Act (as reported) and the PATENT Act would require the written consent of the manufacturer to obtain a stay of an action against a customer only if the manufacturer had been made a party to the action on motion by the customer.<sup>126</sup> The PATENT Act contains the same provisions as the Innovation Act pertaining to situations in which a stay may be lifted: if the action involving the manufacturer will not resolve major issues in the suit against the customer, or the stay unreasonably prejudices or is manifestly unjust to the party seeking to lift the stay.<sup>127</sup> Also like the Innovation Act, the PATENT Act would exempt from the customer suit stay provision any action that includes a cause of action for patent infringement under 35 U.S.C. Section 271(e)(2).<sup>128</sup>

## Shifting of Attorney Fees

For many years, patent cases were subject to the “American Rule,” under which “[e]ach litigant pays his own attorney fees, win or lose.”<sup>129</sup> Then in 1947, Congress enacted a fee-shifting provision that gave district courts the power to award attorney fees to the prevailing party in

---

<sup>123</sup> *Id.*, adding revised 35 U.S.C. §296(d).

<sup>124</sup> H.Rept. 113-279, p. 30.

<sup>125</sup> S. 1137, §4, adding new 35 U.S.C. §299A.

<sup>126</sup> H.R. 9 (as reported), §5, adding revised 35 U.S.C. §296(b)(4); S. 1137, §4, adding new 35 U.S.C. §299A(c).

<sup>127</sup> S. 1137, §4, adding new 35 U.S.C. §299A(d).

<sup>128</sup> *Id.*, adding new 35 U.S.C. §299A(b).

<sup>129</sup> *Marx v. General Revenue Corp.*, 133 S. Ct. 1166, 1175 (2013); see also *Alyeska Pipeline Service Co. v. Wilderness Society*, 421 U.S. 240, 247-53 (1975) (explaining that “[i]n the United States, the prevailing litigant is ordinarily not entitled to collect a reasonable attorneys’ fee from the loser.”).

patent suits. The 1952 revision of the patent laws codified this provision at 35 U.S.C. Section 285. This section of the Patent Act provides a court with the discretion to award “reasonable” attorney fees to the prevailing party (plaintiff or defendant) only “in exceptional cases.”

However, the Federal Circuit in its 2005 opinion, *Brooks Furniture Manufacturing, Inc. v. Dutailier International, Inc.*,<sup>130</sup> established that courts may find an “exceptional case” under Section 285 in only two limited circumstances: (A) “when there has been some material inappropriate conduct” (during the litigation or in obtaining the patent from the USPTO) or (B) when the litigation is both (1) brought in subjective bad faith and (2) objectively baseless. In addition, *Brooks Furniture* held that the prevailing party must prove its entitlement to attorney fees by “clear and convincing evidence.”<sup>131</sup> In part due to this strict standard, federal judges have rarely award these fees.<sup>132</sup>

In April 2014, the Supreme Court in *Octane Fitness v. Icon Health & Fitness* unanimously overruled the Federal Circuit’s *Brooks Furniture* standard because the two-prong test “is unduly rigid, and it impermissibly encumbers the statutory grant of discretion to district courts.”<sup>133</sup> Instead, the Court adopted a more lenient standard, holding “that an ‘exceptional’ case is simply one that stands out from others with respect to the substantive strength of a party’s litigating position (considering both the governing law and the facts of the case) or the unreasonable manner in which the case was litigated.”<sup>134</sup> The Court explained that district courts must make the Section 285 determination by considering the “totality of the circumstances.”<sup>135</sup> The Court also rejected the Federal Circuit’s requirement that prevailing parties establish their entitlement to legal fees by “clear and convincing evidence” and instead embraced a “preponderance of the evidence” standard.<sup>136</sup> In a companion case decided the same day as *Octane Fitness*, the Supreme Court in *Highmark v. Allcare Health Management*<sup>137</sup> rejected the Federal Circuit’s position that a district court’s “exceptional case” determination is to be reviewed on appeal “de novo” and “without deference.” Instead, the Court held that the district court’s Section 285 determination must be reviewed on appeal under an abuse-of-discretion standard.<sup>138</sup>

By overruling the Federal Circuit’s restrictive interpretation of Section 285, *Octane Fitness* and *Highmark* provide district courts with greater discretion in deciding whether to award fees, thus likely increasing the number of patent cases in which attorney fees are shifted. Thus, in evaluating whether to award attorney fees, a court must first assess whether the case is “exceptional” in accordance with the standard announced in *Octane Fitness*, and if so, the court may (or may not) choose to award the fees. It is unclear the extent to which these recent Supreme Court decisions will impact the filing of patent infringement lawsuits by patent assertion entities, yet supporters of patent litigation reform express hope that the increased prospect of paying the

---

<sup>130</sup> *Brooks Furniture Mfg., Inc. v. Dutailier Intern., Inc.*, 393 F.3d 1378 (Fed. Cir. 2005) (*overruled by Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, No. 12-1184, slip op. (2014)).

<sup>131</sup> *Id.* at 1382.

<sup>132</sup> See Randall R. Rader et al., *Make Patent Trolls Pay in Court*, N.Y. TIMES, June 4, 2013, available at [http://www.nytimes.com/2013/06/05/opinion/make-patent-trolls-pay-in-court.html?\\_r=0](http://www.nytimes.com/2013/06/05/opinion/make-patent-trolls-pay-in-court.html?_r=0) (noting that “fees were shifted under Section 285 in only 20 out of nearly 3,000 patent cases filed in 2011.”).

<sup>133</sup> *Octane Fitness, LLC v. ICON Health & Fitness, Inc.*, No. 12-1184, slip op. at 1 (2014).

<sup>134</sup> *Id.* at 7.

<sup>135</sup> *Id.* at 8.

<sup>136</sup> *Id.* at 11.

<sup>137</sup> *Highmark Inc. v. Allcare Health Mgmt.Sys.*, No. 12-1163, slip. op. (2014).

<sup>138</sup> *Id.* at 5.



other party's litigation expenses could be a significant financial disincentive to PAEs' litigation tactics.<sup>139</sup> However, some observers predict that *Octane Fitness* and *Highmark* will not have a significant impact on PAEs because fee-shifting will remain limited:

[R]ecent Supreme Court cases ... make clear that a case is exceptional only if it is unusually weak. Moreover, because district courts now have substantial discretion to decide whether to award fees, district courts that signal a reluctance to shift fees will invariably attract greater proportions of future patent lawsuits from plaintiffs eager to avoid any risk of fee-shifting. Finally, even when a court does shift fees to a plaintiff, the shell-corporation structure of many abusive litigants precludes any meaningful recovery for the defendant. So long as the entity that owns the patent rights holds no other assets, patent plaintiffs can effectively render themselves judgment proof.<sup>140</sup>

Section 3(b) of the Innovation Act would amend Section 285 to require a court, in any patent case, to award attorney fees to a prevailing party (plaintiff or defendant), *unless* the court finds that either

1. the nonprevailing party's position and conduct are "reasonably justified in law and fact"<sup>141</sup> or
2. there are "special circumstances (such as severe economic hardship to a named inventor) [that] make an award unjust."<sup>142</sup>

Although not explicitly stated by the legislation, the nonprevailing party would appear to have the burden of demonstrating the existence of either of these exceptions in order to rebut the presumption of an award of attorney fees. Supporters of the Innovation Act's fee-shifting provision believe that "allowing more liberal shifting of attorney fees against losing parties would reduce the frequency of such nuisance settlements, and would allow more defendants to challenge patents that are invalid or that have been asserted beyond what their claims reasonably allow."<sup>143</sup> On the other hand, those wary of fee-shifting provisions are concerned that they may benefit wealthy corporate parties to the disadvantage of individual inventors. They assert that "[a] 'loser pays' provision will deter patent holders from pursuing meritorious patent infringement claims and protects institutional defendants with enormous resources who can use the risk of fee-shifting to force inventors into accepting unfair settlements or dismissing their legitimate claims."<sup>144</sup>

The Support Technology and Research for Our Nation's Growth (STRONG) Patents Act of 2015 (S. 632) does not include a fee-shifting provision; instead, Section 101 of S. 632 (the "findings" section) asserts that the Supreme Court's *Octane Fitness* and *Highmark* rulings "significantly reduced the burden on an alleged infringer to recover attorney fees from the patent owner, and increased the incidence of fees shifted to the losing party."<sup>145</sup>

<sup>139</sup> Daniel Fisher, *Patent Trolls Face Higher Risks As Supreme Court Loosens Fee-Shifting Rule*, Forbes, April 29, 2014, at <http://www.forbes.com/sites/danielfisher/2014/04/29/patent-trolls-face-higher-risks-as-supreme-court-loosens-fee-shifting-rule/>.

<sup>140</sup> *Examining Recent Supreme Court Cases in the Patent Area: Hearing Before the House Judiciary Comm., Subcomm. on Courts, Intellectual Property, and the Internet*, 114<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2015) (Statement of Andrew J. Pincus, Partner, Mayer Brown LLP), at 3, available at [http://judiciary.house.gov/\\_cache/files/43c13fd8-8287-4a3f-b172-67a0b37d236f/02.12.15-pincus-testimony.pdf](http://judiciary.house.gov/_cache/files/43c13fd8-8287-4a3f-b172-67a0b37d236f/02.12.15-pincus-testimony.pdf).

<sup>141</sup> H.R. 9, §3(b), adding revised 35 U.S.C. §285(a).

<sup>142</sup> *Id.*

<sup>143</sup> H.Rept. 113-279, at 21.

<sup>144</sup> *Id.* at 107 (quoting a letter from the American Association for Justice).

<sup>145</sup> S. 632, §101(12).



Section 7(a) of the PATENT Act expresses a “sense of Congress that, in patent cases, reasonable attorney fees should be paid by a nonprevailing party whose litigation position or conduct is not objectively reasonable.”<sup>146</sup> Unlike the Innovation Act’s creation of what appears to be a presumption of an award of attorney fees, Section 7(b) of the PATENT Act would require the prevailing party to first make a motion for the fees, after which the court must determine whether the position of the nonprevailing party was “objectively reasonable in law and fact, and whether the conduct of the nonprevailing party was objectively reasonable.” If the court finds that the nonprevailing party’s position and conduct does not satisfy these standards, the court must award reasonable attorney fees to the prevailing party, unless special circumstances would make an award unjust.<sup>147</sup> On June 4, 2015, the Senate Judiciary Committee approved two additions to the PATENT Act’s fee-shifting provision:<sup>148</sup>

1. An explicit statement that “[t]he prevailing party shall bear the burden of demonstrating that the prevailing party is entitled to an award.”
2. Examples of what constitutes a “special circumstance()... that would make an award unjust:” such as undue economic hardship to either—
  - a. a named inventor (the same party cited by the Innovation Act) or
  - b. an institution of higher education (as defined in section 101(a) of the Higher Education Act of 1965 (20 U.S.C. §1001(a)) (a party not listed in the Innovation Act’s comparable fee-shifting provision)

Some practitioners believe that the Innovation Act’s fee-shifting provision “would likely require fee awards in more cases than” the PATENT Act’s comparable provision.<sup>149</sup>

Unlike the Innovation Act, the PATENT Act would exempt from the fee-shifting provision any action that includes a cause of action for patent infringement under 35 U.S.C. Section 271(e)(2).<sup>150</sup>

### Recovery of Fee Awards from Interested Parties

The Federal Rules of Civil Procedure outline when a person must and may join as a party in litigation. Under Rule 19, a person must join as a party if, in the person’s absence, the court would be unable to accord complete relief among existing parties, the person is unable to protect an interest, or a present party would be subject to a substantial risk of incurring multiple obligations.<sup>151</sup> Under Rule 20, a person may join as a plaintiff if all the plaintiffs could claim a right to relief for injuries arising from the same occurrence or transaction.<sup>152</sup> Likewise, persons may be joined as defendants if any right to relief is asserted against them jointly, severally, or in the alternative with respect to or arising out of the same transaction or occurrence.<sup>153</sup> The Patent

<sup>146</sup> S. 1137, §7(a).

<sup>147</sup> S. 1137, §7(b), *adding revised* 35 U.S.C. §285(a).

<sup>148</sup> S. 1137 (as reported), §7(b), *adding revised* 35 U.S.C. §285(a).

<sup>149</sup> Ryan Davis, *4 Differences in the House and Senate Patent Troll Bills*, Law360.com, April 30, 2015 (citing the views of several patent litigators).

<sup>150</sup> S. 1137, §7(b), *adding revised* 35 U.S.C. §285(d)(1). However, the PATENT Act would permit a court, in exceptional cases, to award reasonable attorney fees to the prevailing party in a civil action that includes a claim for relief arising under Section 271(e). *Id.*, *adding revised* 35 U.S.C. §285(d)(2).

<sup>151</sup> Fed. R. Civ. P. 19.

<sup>152</sup> Fed. R. Civ. P. 20.

<sup>153</sup> *Id.*

Act outlines more specific joinder requirements for a patent civil action. Under the Patent Act, a party may join a patent civil action as a defendant (accused infringer) only if any right to relief is asserted against the parties jointly and severally,<sup>154</sup> or arises out of the same transaction relating to the making, using, importing into the United States, offering for sale, or selling of the same accused product/process.<sup>155</sup> All defendants in the action must share the same questions of fact for joinder to occur.<sup>156</sup> Joinder cannot occur if “based solely on allegations that they each have infringed the patent or patents in suit.”<sup>157</sup>

Section 3(c) of the Innovation Act would establish mandatory joinder rules when the nonprevailing party alleging infringement is unable to pay the fee award ordered by the court and other expenses. Thus, this provision would require a court presiding over a patent case to grant a defendant’s motion to join an “interested party,” “if such defending party shows that the plaintiff has no substantial interest<sup>158</sup> in the patent or patents at issue other than asserting such patent claim in litigation.”<sup>159</sup> An “interested party” subject to this joinder provision would include a party that is a patent assignee, has a right to enforce or sublicense the patent, or has a direct financial interest in the patent, such as the right to any part of a damage award or licensing revenue.<sup>160</sup> The bill would exclude from the definition of an “interested party”

1. the plaintiff’s employees;<sup>161</sup>
2. legal counsel retained on a contingency fee basis; or
3. an individual “whose sole financial interest in the patent or patents at issue is ownership of an equity interest in the party alleging infringement, unless such person also has the right or ability to direct or control the civil action.” (“[M]embership on the board of directors alone is not sufficient to demonstrate such right or ability.”)<sup>162</sup>

The Innovation Act (as reported) would create a statutory exception to the applicability of the joinder of interested parties provision for technology transfer organizations whose primary purpose is to facilitate the commercialization of technologies developed by one or more institutions of higher education, if such technology transfer organization is alleging infringement on behalf of an entity that is exempted from the joinder provision.<sup>163</sup>

<sup>154</sup> Joint and several liability occurs when two or more people are found liable, and the plaintiff may collect the entire judgment from any one of the parties or from any and all of the parties in various amounts until the judgment is paid in full. *See* Black’s Law Dictionary, 2d. ed.

<sup>155</sup> 35 U.S.C. §299(a).

<sup>156</sup> *Id.*

<sup>157</sup> *Id.* §299(b).

<sup>158</sup> The Manager’s Amendment to the Innovation Act provided a definition of “substantial interest” to include an interest in the subject matter of a patent at issue if the party: (A) invented the subject matter, or (B) commercially practices or implements or is engaged in research and development in technology in the field of the subject matter. H.R. 9 (as reported), §3(c), *adding new* 35 U.S.C. §299(d)(7).

<sup>159</sup> H.R. 9, §3(c), *adding new* 35 U.S.C. §299(d)(1).

<sup>160</sup> H.R. 9 (as reported), §3(c), *adding new* 35 U.S.C. §299(d)(6)(A)-(C).

<sup>161</sup> This additional exclusion to the “interested party” definition was added by the Manager’s Amendment to the Innovation Act. *See* H.R. 9 (as reported), §3(c), *adding new* 35 U.S.C. §299(d)(6)(C)(i).

<sup>162</sup> This clarification to the “right or ability to direct or control the civil action” was added by the Manager’s Amendment to the Innovation Act. *See* H.R. 9 (as reported), §3(c), *adding new* 35 U.S.C. §299(d)(6)(C)(iii).

<sup>163</sup> H.R. 9 (as reported), §3(c), *adding new* 35 U.S.C. §299(d)(5).

In order for the joinder provision to apply to a patent infringement action, the Innovation Act (as reported) would require the defendant to file an initial statement (no later than 14 days before a scheduling conference is to be held or a scheduling order is due) expressing the good faith belief that the party alleging infringement has no substantial interest in the subject matter at issue other than asserting the patent in litigation.<sup>164</sup> Within 45 days of being served with such an initial statement, the plaintiff would then be required to file a certification that

1. the party will have sufficient funds to pay for any potential award of reasonable attorney fees;
2. the party has substantial interest in the subject matter at issue other than asserting the patent in litigation; or
3. there are no other interested parties.<sup>165</sup>

The Innovation Act would grant the court with the *discretion* to deny a motion to join if the interested party is not subject to service of process, or if the joinder would deprive the court of subject matter jurisdiction or render the venue improper.<sup>166</sup> The Innovation Act would *require* a court to deny a motion to join an interested party if the party did not receive “timely notice” of being identified as an interested party.<sup>167</sup> (The Innovation Act defines “timely notice” to mean actual notice, provided within 30 days after the expiration of when the plaintiff’s certification (described above) is required to be filed, that the party has been identified in the plaintiff’s initial disclosure regarding entities that have financial interests in the patent and which may be liable for paying an award of fees if the plaintiff is unable to pay it.<sup>168</sup>)

A court would also be required to deny a motion to join an interested party if the interested party, within 30 days after receiving the notice described above, renounces in writing and with notice to the court and parties to the action, any ownership, right, or direct financial interest in the patent at issue.<sup>169</sup>

The Innovation Act would provide a court with discretionary authority to make an “interested party” who was joined under Section 3(c) of the act liable for any part of the award of attorney fees that the nonprevailing party is unable to pay.<sup>170</sup>

Mandatory joinder provisions, including that proposed by the Innovation Act, respond to the alleged lack of transparency regarding PAEs or the absence of financial resources held by some PAEs and their corresponding inability to pay fees to a prevailing defendant. Proponents of this proposed provision state that mandatory joinder would encourage greater transparency by granting patent defendants with further knowledge regarding all the parties who may have an interest in the litigation beyond the PAE “shell company.”<sup>171</sup> Proponents of the joinder provision also argue that such a change would allow prevailing defendants to seek a greater financial award

<sup>164</sup> *Id.*, §3(c), adding new 35 U.S.C. §299(d)(4)(A).

<sup>165</sup> *Id.*, §3(c), adding new 35 U.S.C. §299(d)(4)(B). The Manager’s Amendment to the Innovation Act states that the joinder provision “shall not apply to an action” if the plaintiff files this certification.

<sup>166</sup> H.R. 9, adding new 35 U.S.C. §299(d)(2)(A).

<sup>167</sup> *Id.*, adding new 35 U.S.C. §299(d)(2)(B)(i).

<sup>168</sup> H.R. 9 (as reported), adding new 35 U.S.C. §299(d)(3).

<sup>169</sup> H.R. 9, adding new 35 U.S.C. §299(d)(2)(B)(ii).

<sup>170</sup> H.R. 9, §3(b), adding revised 35 U.S.C. §285(b).

<sup>171</sup> Hearing on H.R. 3309 Innovation Act Before the House Committee on the Judiciary, Subcommittee on Courts, Intellectual Property, and the Internet, 113<sup>th</sup> Cong., 1<sup>st</sup> Sess., (2013) (Statement of Kevin T. Kramer, Vice President and Deputy General Counsel for Intellectual Property, on behalf of Yahoo! Inc.).

against PAEs, who may not have extensive financial resources, by permitting the defendants to seek financial recovery against additional parties.<sup>172</sup> Opponents of this provision argue that the mandatory joinder of third parties is “one-sided” and may restrict the ability of patent owners to enforce their patents.<sup>173</sup> Some have stated that joinder provisions such as the one proposed by the Innovation Act may harm business relationships that arise through licensing by forcing parties to join in order to pay damages and other fees.<sup>174</sup> Opponents also contend that joinder in this context for the purposes of fee-shifting raises constitutional concerns as the provision would create standing for parties that would otherwise not have standing.<sup>175</sup> Specifically, the opponents point to the scenario where “a defendant may join [as] a third-party at the end of the case for the purposes of fee-shifting, but the third-party had no standing to assert or defend themselves during the course of the legal proceedings.”<sup>176</sup>

The PATENT Act contains a mechanism for recovering fee awards from interested parties that is similar to the Innovation Act (as reported). First, the PATENT Act’s recovery of award provision would allow the defendant to file (no later than 14 days before a scheduling conference is to be held or a scheduling order is due) an initial statement expressing the good faith belief that the primary business of the plaintiff is the assertion and enforcement of patents (or the licensing that results from it).<sup>177</sup> Within 45 days of being served with such an initial statement, the plaintiff would then be required to file a certification that<sup>178</sup>

1. the party will have sufficient funds to pay for any potential award of reasonable attorney fees;
2. the party’s primary business is not the assertion and enforcement of patents (or the licensing that results from it);
3. the identity of “interested parties,” if any; or
4. it has no such interested parties.

The PATENT Act defines “interested party” for purposes of this section concerning the recovery of fees, to mean a person who has a substantial financial interest related to the proceeds from any settlement, license, or damages award resulting from the enforcement of the patent in the action.<sup>179</sup> However, the term does NOT include any of the following:<sup>180</sup>

1. an attorney or law firm providing legal representation in the action if the sole basis for its financial interest in the action arises from compensation related to the provision of legal representation;

<sup>172</sup> *Protecting Small Businesses and Promoting Innovation by Limiting Patent Troll Abuse: Hearing Before the Senate Judiciary Comm.*, 113<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2013) (Statement of Philip S. Johnson, Chief Intellectual Property Counsel, Johnson & Johnson).

<sup>173</sup> *The Impact of Abusive Patent Litigation Practices on the American Economy: Hearing Before the Senate Judiciary Comm.*, 114<sup>th</sup> Cong. 1<sup>st</sup> Sess. (2015) (Statement of Hans Sauer, Ph.D., Deputy General Counsel for Intellectual Property, on behalf of Biotechnology Industry Organization).

<sup>174</sup> *Id.*

<sup>175</sup> H.Rept. 113-279, p. 109.

<sup>176</sup> *Id.*

<sup>177</sup> S. 1137, §7(b), *adding revised* 35 U.S.C. §285(c)(1)(A).

<sup>178</sup> *Id.*, *adding revised* 35 U.S.C. §285(c)(1)(B).

<sup>179</sup> *Id.*, *adding revised* 35 U.S.C. §285(c)(2)(A),

<sup>180</sup> *Id.*, *adding revised* 35 U.S.C. §285(c)(2)(B), (C), and (D).

2. a person who has assigned all right, title, and interest in a patent, except for passive receipt of income to an institution of higher education or a nonprofit technology transfer organization affiliated with the institution;
3. a person who would otherwise meet the definition of an interested party but whose financial interest is based solely on an equity or security interest that had been initially established when the party alleging infringement's primary business was not the assertion and enforcement of patents (or the licensing resulting from it); and
4. an insured depository institution whose sole basis for the financial interest arises from a loan or other debt obligation.<sup>181</sup>

The PATENT Act would place an ongoing duty on the plaintiff to update its certification within 30 days after a material change to any of the information provided within it.<sup>182</sup> Prior to filing the certification, the plaintiff must provide each identified interested party “actual notice in writing by service of notice in any district where the interested party may be found,” in order to establish jurisdiction over the interested party for the sole purpose of enforcing an award of attorney fees, “consistent with the Constitution of the United States.”<sup>183</sup> The notice must identify the action, the parties, the patents at issue, and the interest qualifying the party to be an interested party. The notice must also inform the recipient that the recipient may be held accountable for any award of attorney fees (or a portion thereof) resulting from the action in the event the plaintiff cannot satisfy the full amount of such award, unless the recipient submits a statement to the court and parties in the action, within 120 days of receiving the notice, that renounces its interest related to the enforcement of the patent.<sup>184</sup> The PATENT Act would make any interested parties who are timely served with this notice potentially liable to pay any attorney fees, or portion thereof, awarded by the court, in the event that the party alleging infringement cannot satisfy the full amount of the award.<sup>185</sup> However, interested parties would not be accountable if “a true and correct certification” is filed with the court that the plaintiff will have sufficient funds to pay for any potential award of reasonable attorney fees, or that the party’s primary business is not the assertion and enforcement of patents (or the licensing that results from it).<sup>186</sup>

The PATENT Act grants an interested party the right to intervene in the action for purposes of contesting its identification as an interested party or its liability for attorney fees.<sup>187</sup> A court may, in the interest of justice, exempt from award recovery any party identified as an interested party. Finally, the PATENT Act would create a statutory exception to the applicability of the award recovery provision for any institution of higher education (as defined in 20 U.S.C. §1001(a), or under equivalent laws in foreign jurisdictions), or a non-profit technology transfer organization whose primary purpose is to facilitate the commercialization of technologies developed by one or

---

<sup>181</sup> This additional exclusion to the “interested party” definition was added by the Manager’s Amendment to the PATENT Act, which was approved by the Senate Judiciary Committee. *See* S. 1137 (as reported), §7(b), *adding revised* 35 U.S.C. §285(c)(2)(E).

<sup>182</sup> *Id.*, *adding revised* 35 U.S.C. §285(c)(1)(B).

<sup>183</sup> *Id.*, *adding revised* 35 U.S.C. §285(c)(1)(C).

<sup>184</sup> *Id.*

<sup>185</sup> *Id.*, *adding revised* 35 U.S.C. §285(c)(1)(D).

<sup>186</sup> *Id.*

<sup>187</sup> *Id.*, *adding revised* 35 U.S.C. §285(c)(1)(G).

more institutions of higher education.<sup>188</sup> These entities must file with the court a certification that they qualify for this exception and provide notice to the parties in the action.

## Demand Letters

A patent demand letter is a letter sent by a patent-holder to a company or an individual accusing the recipient of patent infringement. The letters tend to demand that the alleged infringer take a specific action such as ceasing the infringing action or agreeing to a licensing arrangement. A patentee may use demand letters to prove willfulness in a patent infringement lawsuit, a high bar after recent court decisions. In the 2007 case, *In re Seagate Technology*, the Federal Circuit established a two-pronged test for willful infringement in a patent case. First, the patentee must show, by clear and convincing evidence, “that the infringer acted despite an objectively high likelihood that its actions constituted infringement of a valid patent.”<sup>189</sup> Then the patentee must prove “subjective recklessness,” which means that the accused infringer knew or should have known the risk of infringement.<sup>190</sup> A detailed demand letter, including a summary of the alleged patent infringement, helps to establish that the recipient/alleged infringer has the high degree of knowledge to meet this standard. Current law, however, does not dictate any specific content requirements or level of detail for demand letters.

The Innovation Act states that it is the “sense of Congress” that “it is an abuse of the patent system and against public policy for a party to send out purposely evasive demand letters to end users alleging patent infringement.”<sup>191</sup> H.R. 9 also states that any claimant asserting willful infringement may not rely on demand letters as notification of infringement unless the letter identifies with particularity the asserted patent, the product or process accused, and the ultimate parent entity of the claimant, and explains how the product or process infringes to the extent possible.<sup>192</sup>

H.R. 1896, the “Demand Letter Transparency Act of 2015,” outlines both content and disclosure requirements for demand letters. The bill would require any entity that sends 20 or more demand letters during any 365-day period to submit to the USPTO a disclosure identifying

- the patent, including a confirmation that the entity that sent the letter is the owner of the patent and is the last recorded entity in USPTO records for purposes of assignment, grant, or conveyance;
- the entity that has the right to license the patent or the name of the exclusive licensee;
- each entity asserting a claim with regard to the patent;
- each obligation to license the patent and the financial terms at which such patent has been licensed;
- the ultimate parent entity of such entity;
- the number of recipients of the letter;
- any case that has been filed by such entity relating to such patent; and

<sup>188</sup> *Id.*, adding revised 35 U.S.C. §285(c)(1)(F).

<sup>189</sup> *In re Seagate Technology*, 497 F.3d 1360, 1371 (Fed. Cir. 2007).

<sup>190</sup> *Id.* at 1371-72.

<sup>191</sup> H.R. 9, §3.

<sup>192</sup> *Id.*



- any ex parte review or inter partes review of such patent.<sup>193</sup>

In order to enforce these proposed disclosure requirements, H.R. 1896 would permit a court in a patent infringement or validity action brought by an entity that does not meet such USPTO disclosure requirements to sanction such entity for an amount to be awarded to the adverse party to cover any costs incurred as a result of such violation.<sup>194</sup> The bill would exempt from these disclosure requirements original or joint inventors, institutions of higher education, and technology transfer organizations facilitating the commercialization of technology developed by institutions of higher education.<sup>195</sup>

In addition to the disclosure requirements, the Demand Letter Transparency Act of 2015 would require any demand letter sent to another entity to include specified information concerning

- each claim of each patent allegedly infringed, including each accused instrumentality;
- each party alleging infringement;
- the direct infringement for each claim alleged to have been infringed indirectly;
- the principal business of the party alleging infringement;
- each complaint filed that asserts or asserted any of the same patents, each case filed by such entity, and any ex parte or inter partes review for each patent;
- whether the patent is subject to any licensing term or pricing commitments;
- owners, co-owners, assignees, or exclusive licensees of the patent;
- any person who has a legal right to enforce the patent;
- any person with a direct financial interest in the outcome of the action; and
- how the recipient can access the USPTO demand letter database.<sup>196</sup>

Under the House's TROL Act<sup>197</sup> and the Senate's STRONG Patents Act,<sup>198</sup> a demand letter would qualify as an "unfair or deceptive act or practice" under the Federal Trade Commission Act<sup>199</sup> if the sender states or represents *wrongly* and *in bad faith* that

- the sender is a person with the right to license and enforce the patent;
- a civil action asserting a claim of infringement has been filed against the recipient;
- a civil action asserting a claim of infringement has been filed against other persons;
- legal action for infringement of the patent will be taken against the recipient;
- the sender is the exclusive licensee of the patent;

---

<sup>193</sup> H.R. 1896, §2, *adding new* 35 U.S.C. §263.

<sup>194</sup> *Id.*

<sup>195</sup> *Id.*

<sup>196</sup> H.R. 1896, §3, *adding new* 35 U.S.C. §264. H.R. 1896, §2 also would require the USPTO to establish a demand letter database that is publicly accessible and searchable.

<sup>197</sup> H.R. 2014.

<sup>198</sup> S. 632.

<sup>199</sup> 15 U.S.C. §45(a)(1).



- persons other than the recipient purchased a license for the patent asserted in the letter;
- persons other than the recipient purchased an unrelated license and it is not identified as such;
- an investigation of the recipient's infringement occurred.<sup>200</sup>

The TROL Act and the STRONG Patents Act also would consider demand letters as unfair practices if the sender in bad faith seeks compensation for

- a patent that is held to be unenforceable or invalid in a final determination;
- activities taken by the recipient after expiration of the asserted patent;
- activity of the recipient that the sender knew was authorized by a person with the right to license the patent.<sup>201</sup>

Demand letters would also qualify as unfair practices under the TROL Act and the STRONG Patents Act if the sender fails to include

- the identity of the person including the name of the parent entity unless such person is a public company and the name of the public company is identified;
- an identification of at least one patent allegedly infringed;
- an identification of at least one product or service of the recipient infringing the identified patent;
- a name and contact information of a person the recipient may contact about the assertions or claims.<sup>202</sup>

Under both the TROL Act and the STRONG Patents Act, the Federal Trade Commission would enforce any violations of the provisions above.<sup>203</sup> This provision would also preempt any state law “expressly relating to the transmission or contents of communications relating to the assertion of patent rights.”<sup>204</sup>

The Senate's PATENT Act addresses both abusive demand letters and demand letters sent as pre-suit notification. Section 9 of the Senate's PATENT Act would impose civil penalties on a person who has engaged in widespread abusive demand letter practices and has committed an unfair or deceptive act within the meaning of Section 5 of the Federal Trade Commission Act.<sup>205</sup> This bill outlines abusive demand letter practices as communications that falsely represent judicial relief or threaten litigation, and contain assertions that lack a reasonable basis in law or fact because the person does not have the right to assert the patent, the patent has expired, the patent is unenforceable, or the person has falsely represented that an infringement has occurred.<sup>206</sup> Similar to the enforcement provision outlined in the Senate's STRONG Patents Act, the Federal Trade Commission would enforce any violations of this particular provision. The Senate's PATENT Act would also require pre-suit notice letters that accuse a party of infringement to identify each

---

<sup>200</sup> S. 632, §202.

<sup>201</sup> *Id.*

<sup>202</sup> *Id.*

<sup>203</sup> *Id.* §203.

<sup>204</sup> *Id.* §204.

<sup>205</sup> S. 1137, §9, *adding new* 35 U.S.C. §299D.

<sup>206</sup> *Id.*

patent believed to be infringed, to identify the allegedly infringing product, to describe why the plaintiff believes each patent identified is infringed, and to identify the person who can rightfully enforce the patent, as well as additional information.<sup>207</sup> The bill also states that if the plaintiff is seeking to establish willful infringement, then he may not rely on evidence of pre-suit notification of infringement unless that evidence includes this information.

On June 4, 2015, the Senate Judiciary Committee approved several amendments to the PATENT Act relating to demand letters, the most substantial of which would prohibit the pre-suit notice letter to contain (1) a request for, demand for, or offer to accept a specific monetary amount in exchange for a license, settlement, or similar agreement to resolve allegations of patent infringement; or (2) a specific monetary amount demanded based on the cost of legal defense in a lawsuit concerning any asserted claim.<sup>208</sup>

Commentators often associate vague demand letters with PAEs using these letters for the sole purpose of extracting financial concessions.<sup>209</sup> Supporters of more stringent requirements for demand letters point to vague demand letters as impediments of innovation due to the financial costs relating to litigation or settlement that ultimately arise from receiving these types of communications and the resulting impact on small businesses that cannot afford such costs.<sup>210</sup> Supporters also claim that placing more content-based requirements on demand letters would encourage patent owners to target specific infringers more carefully and likewise, would allow alleged infringers to have a clearer understanding of the infringement claims.<sup>211</sup> Critics of patent legislation have argued, however, that the legislation itself is not sufficiently tailored towards letters sent by PAEs, and additional requirements for patent letters may make “it more difficult for patent owners to communicate with potential licensees and alleged infringers even when those communications are in good faith.”<sup>212</sup>

## Reforms of Patent Trial and Appeal Board’s Proceedings (IPR and PGR)

The Leahy-Smith America Invents Act (AIA)<sup>213</sup> established a new administrative proceeding conducted by the USPTO’s Patent Trial and Appeal Board (PTAB) called a “post grant review” (PGR). In this proceeding, petitioners may challenge the validity of an issued patent based on any ground of patentability (such as unpatentable subject matter, or failure to meet the statutory standards of novelty and nonobviousness).<sup>214</sup> A petition to initiate a PGR must be filed within nine months of the date of patent grant.<sup>215</sup> To initiate a PGR, the petitioner must present

<sup>207</sup> *Id.* §8, adding new 35 U.S.C. §299C.

<sup>208</sup> S. 1137 (as reported), §8, adding new 35 U.S.C. §299C(b)(3).

<sup>209</sup> *See, e.g.*, Brian Fung, “Patent reform advocates are launching a ‘super-coalition’ to whack patent trolls,” *Washington Post*, January 14, 2015.

<sup>210</sup> *Trolling for a Solution: Ending Abusive Patent Demand Letters: Hearing Before the House Energy & Commerce Comm., Subcomm. on Commerce, Manufacturing, and Trade*, 113<sup>th</sup> Cong. 2d Sess. (2014) (Statement of Mark Chandler, Senior Vice President and Chief Compliance Officer, on behalf of Cisco Systems Incorporated).

<sup>211</sup> *Id.*

<sup>212</sup> Gene Quinn & Steve Brachmann, “Demand Letter Legislation Must be Narrowly Tailored,” March 4, 2015, available at <http://www.ipwatchdog.com/2015/03/04/demand-letter-legislation-must-be-narrowly-tailored/id=55365/>.

<sup>213</sup> P.L. 112-29. For more information on this law, see CRS Report R42014, *The Leahy-Smith America Invents Act: Innovation Issues*, by John R. Thomas.

<sup>214</sup> 35 U.S.C. §321(b).

<sup>215</sup> *Id.* §321(c).

information that, if not rebutted, would demonstrate that it is “more likely than not that at least one of the claims” is unpatentable.<sup>216</sup> A PGR must be completed within a year of its commencement, with an extension of six months possible for good cause shown.<sup>217</sup>

The AIA also created a new patent revocation proceeding called an “inter partes review” (IPR). A person who is not the patent owner may file a petition requesting inter partes review nine months after a patent issues or reissues, or the conclusion of any post-grant review, whichever occurs later.<sup>218</sup> In an IPR proceeding, petitioners may challenge the validity of an issued patent only on the basis of prior art consisting of patents or printed publications. As a result, patent challenges under IPR are limited to the patentability issues of novelty and nonobviousness.<sup>219</sup>

To initiate an IPR, the petitioner must demonstrate that there is a “reasonable likelihood” that he or she would prevail with respect to at least one claim.<sup>220</sup> An accused infringer may not petition for an IPR if he or she has already filed a declaratory judgment action in federal court challenging the patent, or more than a year has passed since the date the accused infringer was served with a complaint alleging infringement of that patent.<sup>221</sup> Should the patent survive the IPR proceeding, the individual who commenced the proceeding, along with his privies, are barred in the future from raising issues that were “raised or reasonably could have been raised.”<sup>222</sup>

An IPR must be completed within a year of its commencement, with an extension of six months possible for good cause shown.<sup>223</sup> The timing and scope of the two USPTO patent revocation proceedings described above are as follows:

1. A patent may be challenged at the USPTO on any basis of any patentability issue within nine months from the date the patent issued (by filing a petition for a PGR proceeding).
2. Thereafter, and throughout its entire term, a patent may be challenged at the USPTO only on the grounds of novelty and nonobviousness (via an IPR).

Unlike most of the provisions in the patent litigation reform bills discussed above, which generally are to the benefit of defendants in patent infringement lawsuits, the reforms described in this section appear to favor patent holders who may have their patents challenged in an IPR or PGR; these changes have been championed by patent holders who, in particular, depend on patents to protect their business’s revenue, such as brand-name pharmaceutical companies. However, because some of these changes would arguably make it more difficult to invalidate a patent in an IPR or PGR proceeding, patent assertion entities may also benefit from these amendments. Thus, the changes described below have been criticized as being “at odds” with the goal of addressing abusive patent litigation.<sup>224</sup> Nevertheless, such arguably conflicting reforms to

<sup>216</sup> *Id.* §324(a).

<sup>217</sup> *Id.* §326(a)(11).

<sup>218</sup> *Id.* §311(c).

<sup>219</sup> *Id.* §311(b).

<sup>220</sup> *Id.* §314(a).

<sup>221</sup> *Id.* §315.

<sup>222</sup> *Id.* §315(e).

<sup>223</sup> *Id.* §316(a)(11).

<sup>224</sup> Ryan Davis, *Senate Bill Tips Scales for Patent Owners in AIA Reviews*, Law360.com, June 5, 2015 (describing the surprise of one practitioner that the legislation contains “such substantial changes to AIA reviews that favor patent owners—which will benefit trolls when their patents are challenged—when the rest of the bill appears aimed at aiding infringement defendants.”).

the patent system appear to reflect the compromises that lawmakers believe are necessary to make in order to garner support for the legislation and help secure its passage.

### ***Claim Construction Standard***

The AIA is silent on what claim construction standard is appropriate in the IPR and PGR proceedings conducted by the PTAB. Pursuant to authority granted by the AIA, the USPTO promulgated a regulation in August 2012<sup>225</sup> that provided the following standard for claim construction in an IPR: “[a] claim in an unexpired patent shall be given its broadest reasonable construction in light of the specification of the patent in which it appears.”<sup>226</sup> In a case issued in February 2015 involving a challenge to the USPTO’s rulemaking authority to promulgate this regulation, a divided panel of the Federal Circuit upheld the PTAB’s use of the “broadest reasonable interpretation” (BRI) standard in claim construction.<sup>227</sup> The appellate court noted that the USPTO has long applied the BRI standard in a variety of proceedings, including initial examinations, interferences, and reissue and reexamination proceedings.<sup>228</sup> The Federal Circuit explained that by applying the BRI standard, the USPTO “reduce[s] the possibility that, after the patent is granted, the claims may be interpreted as giving broader coverage than is justified.”<sup>229</sup> The appellate court stated that “Congress is presumed to legislate against the background of existing law where Congress in enacting legislation is aware of the prevailing rule,”<sup>230</sup> and concluded that “Congress implicitly adopted the broadest reasonable interpretation standard in enacting the AIA.”<sup>231</sup>

Section 9 of the Innovation Act and Section 11 of the PATENT Act (as reported) would legislatively overrule the Federal Circuit’s recent decision regarding the use of the BRI standard in patent revocation proceedings. Instead, the Innovation Act and PATENT Act (as reported) would require that the PTAB, in IPR and PGR proceedings, use the same claim construction standard that is applied by federal courts; that is, the PTAB would need to construe a patent claim “in accordance with the ordinary and customary meaning of such claim as understood by one of ordinary skill in the art and the prosecution history pertaining to the patent.”<sup>232</sup>

The Innovation Act and the PATENT Act (as reported) would also require the PTAB to consider prior claim construction by a court in a civil action in which the patent owner was a party.<sup>233</sup>

Sections 102 and 103 of the STRONG Patents Act contain similar amendments regarding the claim construction standard to be used in IPR and PGR proceedings. The PATENT Act does not include a provision that would alter the existing claim construction standard.

Former USPTO Director David Kappos has observed that currently, “the speed mandated for post-grant procedures is leading to greater interaction between court interpretations and USPTO interpretations of the same patent claims, and having the USPTO apply a different standard than

<sup>225</sup> USPTO, *Changes to Implement Inter Partes Review Proceedings, Post-Grant Review Proceedings, and Transitional Program for Covered Business Method*, 77 *Federal Register* 48680 (August 14, 2012) (final rule).

<sup>226</sup> 37 C.F.R. §42.100(b).

<sup>227</sup> *In re Cuozzo Speed Technologies LLC*, 778 F.3d 1271 (Fed. Cir. 2015).

<sup>228</sup> *Id.* at \*16.

<sup>229</sup> *Id.* at \*17 (quoting *In re Prater*, 415 F.2d 1393, 1396 (CCPA 1981)).

<sup>230</sup> *Id.* at \*17.

<sup>231</sup> *Id.* at \*21.

<sup>232</sup> H.R. 9, §9, *adding new* 35 U.S.C. §316(a)(14)(A); S. 1137 (as reported), §11(a)(4)(A)(vii).

<sup>233</sup> *Id.*, *adding new* 35 U.S.C. §316(a)(14)(B).

the courts [for claim construction] is leading, and will continue to lead, to conflicting decisions.”<sup>234</sup> However, he notes that there are valid arguments for retaining the broader standard for post-grant proceedings, such as that the BRI standard “requires patentees to define their claims clearly over the prior art during proceedings” before the USPTO.<sup>235</sup>

Others have asserted that changing the claim construction standard in IPR and PGR from BRI to “ordinary and customary meaning” would be a positive benefit to patent owners who feel that the BRI standard makes it easier to invalidate their patents in the AIA-established post-grant reviews than in federal courts.<sup>236</sup>

However, some groups oppose the inclusion of these changes to the IPR/PGR claim construction standard in the patent litigation reform bills, arguing that they “will undermine post grant review procedures that have proven to be an effective and useful tool in weeding out the weak patents that are often asserted in the most abusive of patent cases.”<sup>237</sup> Technology companies have explained their opposition to the IPR/PGR amendments as follows:

[T]he changes to the claim construction standard in IPR proceedings ... would eliminate a necessary and significant difference between the court system and USPTO standards for claim construction. In district court, the purpose is to determine liability for patent infringement; whereas the purpose of an IPR proceeding is for the USPTO to ensure its decision to issue a patent was, in fact, correct. The IPR process was amended in the AIA to provide a more streamlined, cost-effective method to challenge patent validity outside the court system. The proposed changes to this process endanger the meaningful progress Congress has made in reducing the burden invalid patents pose to our industry and will only make the process more costly and complex.<sup>238</sup>

### *Estoppel Effect of Unsuccessful Challenges in PGR Proceedings*

An individual who commences a PGR proceeding, along with anyone who has a legal interest in the patent, are barred from raising in a later civil action issues that they raised in the administrative review of the validity of a patent claim—as well as any issue that “reasonably could have been raised” during the PGR.<sup>239</sup> Section 9 of the Innovation Act and Section 14(a) of the PATENT Act would narrow the estoppel effect arising from a PGR by removing the phrase “or reasonably could have raised” in the statute.<sup>240</sup> Thus, this provision would effectively permit parties to later assert in a civil action that a patent claim is invalid on any ground that the party

<sup>234</sup> H.R. 3309, the “Innovation Act,” *Hearing Before the House Judiciary Comm., 113<sup>th</sup> Cong., 1<sup>st</sup> Sess.* (2013) (Statement of David J. Kappos, Former Under Secretary of Commerce for Intellectual Property and Director of the United States Patent and Trademark Office), at 8.

<sup>235</sup> *Id.*

<sup>236</sup> Ryan Davis, *Innovation Act Would Revamp AIA Reviews to Shield Patents*, Law360.com, February 10, 2015 (explaining that “[c]onstruing the claims of a patent in an AIA review broadly means that significantly more prior art can be used to invalidate the patent than would be available in district court. A majority of AIA final decisions to date have invalidated at least some claims of the patent.”).

<sup>237</sup> Business Software Alliance (BSA) Letter to Speaker Boehner and Minority Leader Pelosi, July 9, 2015, *available at* <http://www.bsa.org/~media/Files/Policy/SoftwareInnovation/Letters/07092015InnovationActLetter.pdf>, at 1.

<sup>238</sup> Information Technology Industry Council Letter to Senate Judiciary Committee Chairman Grassley and Ranking Member Leahy, June 3, 2015.

<sup>239</sup> 35 U.S.C. §325(e).

<sup>240</sup> H.R. 9, §9(a), *amending* 35 U.S.C. §325(e)(2); S. 1137, §14(a).

“reasonably could have raised” during the PGR. The purpose of this change is apparently to correct an “inadvertent scrivener’s error” made in drafting the AIA.<sup>241</sup>

### ***Presumption of Validity and Burdens of Proof***

The AIA provided that in an IPR or PGR proceeding, “the petitioner shall have the burden of proving a proposition of unpatentability by a preponderance of the evidence.”<sup>242</sup> Sections 102(c) and 103(c) of the STRONG Patents Act would amend existing law to provide a presumption of validity to a previously issued claim that is challenged during an IPR or PGR proceeding.<sup>243</sup> These sections of the legislation would also heighten the evidentiary standard for proving unpatentability of a previously issued claim, requiring that the IPR or PGR petitioner prove such unpatentability “by clear and convincing evidence.”<sup>244</sup>

The PATENT Act (as reported) would amend the statutory provisions governing evidentiary standards for IPR and PGR to provide that “the challenged patent shall be presumed to be valid.”<sup>245</sup> However, the PATENT Act (as reported) does not change the evidentiary standard for proving unpatentability, as the STRONG Patents Act would. One observer has argued that “[a] presumption of validity combined with a preponderance of the evidence standard appears contradictory and creates an illogical process.”<sup>246</sup>

### ***Standing***

On June 11, 2015, the House Judiciary Committee approved amendments to the Innovation Act that would prohibit the institution of an IPR or a PGR unless the petitioner certifies that the petitioner and the real parties in interest of the petitioner<sup>247</sup>

- do not own and will not acquire a financial instrument that is designed to hedge or offset any decrease in the market value of an equity security of the patent owner or an affiliate of the patent owner; and
- have not demanded payment (monetary or otherwise) from the patent owner or an affiliate of the patent owner in exchange for a commitment not to file a petition for IPR with respect to the owner’s patent, unless the petitioner has been sued for or charged with infringement of the patent.

---

<sup>241</sup> See Colleen Chien and Eric Goldman, *In its Rush to Fix Patent Reform, Congress Didn’t Fix Its Biggest Error*, Forbes.com, January 2, 2013; see also 158 Cong.Rec. S8517 (daily ed. December 28, 2012) (statement of Senator Leahy) (“Regrettably, the legislation passed today does not include one technical correction that would improve the law by restoring Congress’s intent for the post-grant estoppel provision of the America Invents Act. Chairman Smith recently described certain language contained in that provision as an ‘inadvertent scrivener’s error.’ As written, it unintentionally creates a higher threshold of estoppel than was in the legislation that passed the Senate 95-5, or that was intended by the House, according to Chairman Smith’s statement. I hope we will soon address this issue so that the law accurately reflects Congress’s intent.”).

<sup>242</sup> 35 U.S.C. §§316(e), 326(e).

<sup>243</sup> S. 632, §102(c), adding revised 35 U.S.C. §316(e)(1); S. 632, §103(c), adding revised 35 U.S.C. §326(e)(1).

<sup>244</sup> *Id.* §102(c), adding revised 35 U.S.C. §316(e)(2); S. 632, §103(c), adding revised 35 U.S.C. §326(e)(2).

<sup>245</sup> S. 1137 (as reported), §11(a)(4)(C)(ii), amending 35 U.S.C. §316(e) (for IPR proceedings); S. 1137 (as reported), §11(b)(4)(C)(ii), amending 35 U.S.C. §326(e) (for PGR proceedings).

<sup>246</sup> Information Technology Industry Council Letter to Senate Judiciary Committee Chairman Grassley and Ranking Member Leahy, June 3, 2015.

<sup>247</sup> H.R. 9 (as reported), §9(b)(1), adding new 35 U.S.C. §316(a)(15) (regarding IPR); H.R. 9 (as reported), §9(b)(1), adding new 35 U.S.C. §326(a)(14) (regarding PGR).



These changes are apparently in response to complaints made by pharmaceutical companies about so-called “reverse trolling” abuses of the PTAB proceedings, such as parties that threaten to challenge patents in IPR proceedings unless patent holders make substantial payments to them, or parties that have strategically used IPR to influence the stock prices of drug companies.<sup>248</sup>

Sections 102(d) and 103(d) of the STRONG Patents Act would provide even more stringent standing requirements for persons wanting to initiate a PGR or IPR. The legislation provides that in order to have standing to file a petition with the USPTO to institute an IPR,<sup>249</sup> a person, or a real party in interest or privy of the person, must show a reasonable possibility of being sued for, or charged with,<sup>250</sup> infringement of the patent. The STRONG Patents Act adjusts the standing requirement slightly for instituting a PGR:<sup>251</sup> a person, or a real party in interest or privy of the person, must demonstrate

- a reasonable possibility of being sued for, or charged with, infringement of the patent; or
- a competitive harm related to the validity of the patent.

### *Institution of an IPR/PGR Proceeding*

The PATENT Act (as reported) would permit the USPTO Director to refuse to institute an IPR or PGR proceeding “if the Director determines that institution would not serve the interest of justice.”<sup>252</sup> The Director would be required to consider several factors in making such determination, including

- whether the grounds of unpatentability are the same as those considered and decided in prior judicial or USPTO proceedings, and
- whether there is another proceeding or matter involving the same patent that is pending before the USPTO.

In addition, the PATENT Act (as reported) would require the USPTO Director to issue regulations governing the composition of panels convened to adjudicate a PGR or IPR, “to ensure that the panel adjudicating such proceeding consists of not more than 1 individual, if any, who participated in the decision to institute such proceeding.”<sup>253</sup>

<sup>248</sup> See H.R. 9, *the Innovation Act: Hearing Before the House Judiciary Comm.*, 114<sup>th</sup> Cong., 1<sup>st</sup> Sess. (2015) (statement of Mr. Hans Sauer, Deputy General Counsel, Biotechnology Industry Organization) (arguing that “the statistically disproportionate ‘kill rates’ of IPR proceedings invite unintended abuses and predatory practices by those seeking to attack patents for illegitimate reasons, including for their own financial gain ...”); see also Joseph Walker & Rob Copeland, *New Hedge Fund Strategy: Dispute the Patent, Short the Stock*, WALL ST. JOURNAL, April 7, 2015 (describing a recent strategy employed by a hedge fund manager, Kyle Bass, in which he files IPR petitions to challenge the validity of patents protecting drugs offered by certain pharmaceutical companies; after filing the IPR, he either shorts the stock of those drug companies (whose stock prices likely fall due to news of the IPR being initiated) or buys shares in other companies that would benefit from the patent being held invalid).

<sup>249</sup> S. 632, §102(d), *adding new* 35 U.S.C. §311(d)(2).

<sup>250</sup> The STRONG Patents Act defines the term “charged with infringement,” for purposes of this standing provision, to mean “a real and substantial controversy regarding infringement of a patent exists such that the petitioner would have standing to bring a declaratory judgment action in Federal court.” S. 632, §102(d), *adding new* 35 U.S.C. §311(d)(1).

<sup>251</sup> S. 632, §103(d), *adding new* 35 U.S.C. §321(d)(2).

<sup>252</sup> S. 1137 (as reported), §11(a)(2), *adding new* 35 U.S.C. §314(a)(2) (regarding IPR); S. 1137 (as reported), §11(b), *adding new* 35 U.S.C. §324(a)(2) (regarding PGR).

<sup>253</sup> S. 1137 (as reported), §11(c)(1).



## Ending Diversion of USPTO Fees

The USPTO is funded entirely by fees it charges to patent and trademark applicants, as well as other entities that interact with the agency.<sup>254</sup> However, the amounts received as fees by the USPTO must still be appropriated by Congress in order for the funds to be available to the agency for obligation or expenditure.<sup>255</sup> Yet over the past 25 years, Congress has often not allocated all of the fees that the USPTO has collected towards the operation of that agency. It has been estimated that, since 1999, over \$1 billion in USPTO fee revenue has been withheld from the USPTO and directed towards unrelated government programs and operations.<sup>256</sup>

The America Invents Act (AIA) that was enacted in 2011 made several changes to the handling of fees collected by the USPTO. Under the AIA, the use of fees generated is still subject to the appropriations process, whereby Congress provides the budget authority for the USPTO to spend these fees. To address the issue of fees withheld from the office in the past, the AIA created within the Treasury a “Patent and Trademark Fee Reserve Fund” into which fee collections above that “appropriated by the Office for that fiscal year” are to be placed.<sup>257</sup> These funds are to be available to the USPTO “to the extent and in the amounts provided in appropriations Acts” and may only be used for the work of the USPTO.<sup>258</sup> However, the USPTO must still obtain congressional authority to use these “excess” funds.

Some argue that USPTO fee diversion is the “single most important problem facing our patent system today” because “continuing fee diversion constitute[s] a tax on innovation and undermine[s] efforts of the USPTO to reduce its backlog [of pending patent applications].”<sup>259</sup>

The STRONG Patents Act would put an end to USPTO fee diversion.<sup>260</sup> Section 107(a) of S. 632 would establish within the U.S. Treasury a revolving fund<sup>261</sup> called the “United States Patent and Trademark Office Innovation Promotion Fund” (Fund). Any fees collected by the USPTO would be deposited into this Fund and would be available to the USPTO Director until they are expended.<sup>262</sup> The amounts in the Fund would be available, without fiscal year limitation, to pay for all expenses of the USPTO, including all administrative and operating expenses that the office incurs.<sup>263</sup>

<sup>254</sup> See *Figueroa v. United States*, 466 F.3d 1023, 1027-28 (Fed. Cir. 2006). The USPTO became fully user-fee funded as a result of P.L. 101-508, the Omnibus Budget Reconciliation Act (OBRA) of 1990. For more information about USPTO’s funding structure, see CRS Report RS20906, *U.S. Patent and Trademark Office Appropriations Process: A Brief Explanation*, by Glenn J. McLoughlin.

<sup>255</sup> In the absence of an appropriation making fees collected by an agency available to that agency, the collected fees are placed in the general fund of the Treasury as miscellaneous receipts, unless otherwise directed. See Government Accountability Office (GAO), Office of the General Counsel, 3 Principles of Federal Appropriations Law 1-12 (2004) (citing 31 U.S.C. §3302(b)).

<sup>256</sup> See Intellectual Property Owners, *USPTO Funding*, at <http://www.ipo.org/index.php/advocacy/hot-topics/uspto-funding/>.

<sup>257</sup> 35 U.S.C. §42(c)(2).

<sup>258</sup> *Id.*

<sup>259</sup> H.Rept. 113-279, p. 104.

<sup>260</sup> A bill introduced in the House, the Innovation Protection Act (H.R. 1832), would similarly end USPTO fee diversion. However, this legislation does not contain provisions unrelated to the funding of the USPTO.

<sup>261</sup> S. 632, §107(a)(4), *adding revised* 35 U.S.C. §42(d)(2).

<sup>262</sup> *Id.* §107(a)(2), *adding revised* 35 U.S.C. §42(c)(1).

<sup>263</sup> *Id.* §107(a)(4), *adding revised* 35 U.S.C. §42(d)(4).

## Venue

Title 28 of the U.S. Code, which governs the federal judicial system, contains a venue statute (Section 1400(b)) specifically applicable to patent cases, providing that “[a]ny civil action for patent infringement may be brought in the judicial district where the defendant resides, or where the defendant has committed acts of infringement and has a regular and established place of business.”<sup>264</sup> However, a 1990 opinion by the Federal Circuit, *VE Holding Corp. v. Johnson Gas Appliance Co.*, applied the general federal venue statute (Section 1391(c)) to patent infringement cases, arguing that Congress, in amending the general venue statute in 1988, intended to change the scope of the patent venue statute in Section 1400(b):

Other than by the clear language of the statute, Congress has not given any indication of whether it intended to change the scope of venue under § 1400(b). If we can infer anything from Congress’ knowledge of the prior judicial interpretation of § 1400(b), given the clear language of the statute, it would be that Congress did intend to change the scope of venue under § 1400(b).<sup>265</sup>

*VE Holding Corp.* thus expanded venue in patent infringement cases beyond what is permitted by Section 1400(b), by allowing the filing of patent infringement lawsuits in “any district where there would be personal jurisdiction over the corporate defendant at the time the action is commenced.”<sup>266</sup> In other words, defendants in patent cases could be sued wherever they offer products for sale. The Federal Circuit’s liberalization of venue in patent cases has led to forum shopping, as plaintiffs (in particular patent assertion entities) seek to file infringement lawsuits in districts where judges and juries have reputations as being particularly favorable to patent holders, such as the Eastern District of Texas.<sup>267</sup>

The Innovation Act (as reported) would effectively overturn *VE Holding Corp.* by imposing limitations on the judicial districts in which a civil action may be brought for patent infringement or for a declaratory judgment that a patent is invalid or not infringed. The reason for this change is to “restore Congress’s intent that patent infringement suits only be brought in judicial districts that have some reasonable connection to the dispute” and to “protect parties against the burden and inconvenience of litigating patent lawsuits in districts that are remote from any of the underlying events in the case.”<sup>268</sup> The Innovation Act (as reported) would expressly exempt the special venue statute for patent actions from the applicability of the general venue statute (28 U.S.C. §1391) and would also revise it to allow an action relating to patents to be brought only in a judicial district<sup>269</sup>

1. where the defendant has its principal place of business or is incorporated;

<sup>264</sup> 28 U.S.C. §1400(b).

<sup>265</sup> *VE Holding Corp. v. Johnson Gas Appliance Co.*, 917 F.2d 1574, 1581 (Fed. Cir. 1990).

<sup>266</sup> *Id.* at 1583.

<sup>267</sup> Ryan Davis, *House Bill Would Shut Down Eastern Texas Patent Docket*, Law360.com, June 12, 2015, at <http://www.law360.com/articles/667339/house-bill-would-shut-down-eastern-texas-patent-docket> (noting that “[u]nder current venue rules, nonpracticing entities are able to buy up patents and rent an office in the Eastern District of Texas in order to establish venue there, then have free rein to sue just about any company in America. Given the district’s reputation and history of large jury awards for patent owners, many nonpracticing entities take advantage of that opportunity.”).

<sup>268</sup> Statement of Chairman Goodlatte, on the Manager’s Amendment to the Innovation Act, available at [http://judiciary.house.gov/index.cfm/hearings?Id=2848E2C2-F705-4A03-800C-64930626A395&Statement\\_id=CF3D1F76-9219-4E6C-9B28-692BD6206E21](http://judiciary.house.gov/index.cfm/hearings?Id=2848E2C2-F705-4A03-800C-64930626A395&Statement_id=CF3D1F76-9219-4E6C-9B28-692BD6206E21).

<sup>269</sup> H.R. 9 (as reported), §3(g)(1), amending 28 U.S.C. §1400(b).

2. where the defendant has committed an act of infringement of a patent in suit and has a regular and established physical facility that gives rise to the act of infringement;
3. where the defendant has agreed or consented to be sued in the instant action;
4. where an inventor named on the patent in suit conducted research or development that led to the application for the patent in suit;
5. where a party has a regular and established physical facility that such party controls and operates (not primarily for the purpose of creating venue) and has
  - a. engaged in management of significant research and development of an invention claimed in a patent in suit prior to the effective filing date of the patent;
  - b. manufactured a tangible product that is alleged to embody an invention claimed in a patent in suit; or
  - c. implemented a manufacturing process for a tangible good in which the process is alleged to embody an invention claimed in a patent in suit

The Innovation Act (as reported) would allow subsection (d) of the general venue statute (28 U.S.C. § 1391(d)) to govern venue for patent cases involving foreign defendants that are not incorporated in the United States or have no regular and established physical facilities in the United States.

## Provisions Concerning Small Businesses

The patent reform litigation legislation introduced in the 114<sup>th</sup> Congress contains several provisions designed to help small businesses that are involved in the patent system either as patent owners or as defendants in infringement lawsuits.

### *Innovation Act and the PATENT Act*

Section 7(a) of the Innovation Act and Section 12 of the PATENT Act would require the USPTO director to develop educational resources for small businesses with respect to their “concerns arising from patent infringement.”<sup>270</sup> Furthermore, the Innovation Act would require that the USPTO’s existing small business patent outreach programs, as well as relevant offices at the Small Business Administration and the Minority Business Development Agency, provide education and awareness on abusive patent litigation practices.<sup>271</sup> Section 7(b) of the Innovation Act and Section 12(b) of the PATENT Act would require the USPTO to create and maintain a “user-friendly” section of its official website, in which the public can find information about patent cases that have been filed in federal court and information about the patent at issue (including the disclosures regarding patent ownership that are mandated by the Innovation Act and PATENT Act). Neither bill authorizes or provides additional appropriations to pay for these initiatives; rather, they are to be implemented using existing agency resources.

Section 8(g) of the Innovation Act would require the USPTO director, in consultation with several heads of relevant agencies and interested parties, to conduct a study that examines the economic impact of the Innovation Act on the ability of individuals and small businesses owned by women, veterans, and minorities to enforce their patent rights. STRONG Patents Act

<sup>270</sup> H.R. 9, §7(a)(1); S. 1137, §12(a)(1).

<sup>271</sup> *Id.* §7(a)(2); S. 1137, §12(a)(2).

Section 111 of the STRONG Patents Act would require the Small Business Administration to produce a report that analyzes the impact of patent ownership by small businesses (those that are independently owned and operated and which are not dominant in their field of operation) and patent infringement actions against small businesses. In addition, the STRONG Patents Act would require the Director of the Administrative Office of the United States to designate at least six U.S. district courts (that are already participating in the patent cases pilot program) “for the purpose of that program to address special issues raised in patent infringement suits against individuals or small business concerns.”<sup>272</sup> These specially designated courts would be required to expedite cases in which an individual or small business concern is accused of patent infringement.<sup>273</sup>

---

<sup>272</sup> S. 632, §111(c)(1).

<sup>273</sup> *Id.* §111(c)(2).

**Table I. Patent Litigation Reform Legislation in the 114<sup>th</sup> Congress**

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Pleading Requirement</b>	<p>Proposed pleading requirements to include:</p> <ul style="list-style-type: none"> <li>• each patent allegedly infringed;</li> <li>• all claims necessary to identify each process, machine, manufacture, or composition of matter alleged to infringe any claim of each patent;</li> <li>• accused instrumentalities;</li> <li>• description of alleged infringement;</li> <li>• authority of plaintiff to assert patent</li> </ul> <p>General description of the above where information is not readily accessible</p> <p>Confidential information may be filed under seal</p> <p>ANDA suit exception</p>	<p>Proposed pleading requirements to include:</p> <ul style="list-style-type: none"> <li>• each patent allegedly infringed;</li> <li>• each claim of each patent allegedly infringed;</li> <li>• accused instrumentalities;</li> <li>• description of infringement</li> </ul> <p>General description where information is not available</p> <p>Confidential information may be filed under seal</p> <p>ANDA suit exception</p>	n/a	n/a	n/a

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Limits on Discovery</b>	<p>Postpone discovery if the defendant makes a motion to dismiss, transfer venue, or sever accused infringers</p> <p>Such motions must be filed within 90 days after service of the complaint and must include a declaration or other evidence in support of the motion</p> <p>Court may allow such discovery that the court deems is necessary to decide those motions</p> <p>Stay of discovery does not apply to an action in which patent holder seeks a preliminary injunction to prevent competitive harm</p> <p>Parties may also consent to exclusion from discovery limitations</p> <p>ANDA suit exception</p>	<p>Discovery stayed pending court's ruling on defendant's motions to dismiss, transfer venue, or sever accused infringers; such motion must be filed prior to the first responsive pleading</p> <p>Court may allow limited discovery necessary to resolve those motions</p> <p>Court may allow additional discovery to preserve evidence or prevent prejudice to party</p> <p>Parties may consent to exclusion from discovery limitations</p> <p>ANDA suit exception</p>	n/a	n/a	n/a



	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Transparency of Patent Ownership</b>	<p>Upon filing of initial complaint for infringement, plaintiff must disclose to USPTO, court, and all adverse parties:</p> <ul style="list-style-type: none"> <li>• Assignee(s) of the patent</li> <li>• Entities with right to sublicense or enforce patent</li> <li>• Entities with financial interest in the patent (right to receive proceeds related to patent assertion) or in the plaintiff (direct or indirect ownership/control of more than 5% of the plaintiff)</li> <li>• Ultimate parent entities (UPE) of the above entities</li> <li>• Description of the principal business of the plaintiff</li> <li>• List of all other complaints filed that assert the patent</li> <li>• Any licensing requirements that patent is subject to</li> </ul> <p>Plaintiff has an ongoing duty to notify USPTO of any changes in the above</p> <p>Failure to comply with duty of disclosure means plaintiff may not recover treble damages or reasonable fees during period of noncompliance; court may award fees to prevailing party for expenses incurred to uncover the updated information</p> <p>ANDA suit exception</p>	<p>Within 14 days of filing the complaint, plaintiff must notify court and adverse parties of:</p> <ul style="list-style-type: none"> <li>• Assignee(s)</li> <li>• Entities with right to sublicense or enforce patent</li> <li>• Entities with financial interest in the patent or in the plaintiff (direct or indirect ownership/control of &gt; 20% of the plaintiff)</li> <li>• UPE of the above</li> <li>• List of other complaints filed in prior 3 years asserting the patent</li> <li>• Any licensing requirements that patent is subject to</li> </ul> <p>Patentee may file this information under seal if confidential</p> <p>Patentee must file information regarding identity of entities with USPTO but no ongoing duty to update the information</p> <p>Assignment of all substantial rights in issued patent (and name of assignee and UPE) must be recorded in USPTO upon grant of patent and whenever subsequent assignments are made</p> <p>Same consequences as Innovation Act for failure to comply with duty to disclose assignment/UPE information to USPTO</p> <p>NO ANDA suit exception</p>	n/a	n/a	n/a

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Stays of Customer- Suits</b>	<p>Court required to suspend/postpone litigation against customer if:</p> <ul style="list-style-type: none"> <li>• manufacturer is party to the civil action or in a separate action involving the patent</li> <li>• customer agrees to be bound by issues decided against the manufacturer</li> <li>• customer requests stay within the later of: 120 days after first pleading is served, or the first scheduling order in the case</li> </ul> <p>Defines “customer” as a retailer or end user who has not materially modified the product/process alleged to infringe the patent</p> <p>Defines “end user” and “retailer” to exclude entities that manufacture the product/process at issue</p> <p>Stay may be lifted if suit against manufacturer will not resolve major issue in suit against customer or if stay unreasonably prejudices or is manifestly unjust to the party seeking to lift it</p> <p>ANDA suit exception</p>	<p>Court required to suspend/postpone litigation against customer if:</p> <ul style="list-style-type: none"> <li>• manufacturer is party to the civil action or in a separate action involving the patent</li> <li>• customer agrees to be bound by issues decided against the manufacturer</li> <li>• Consent of the manufacturer to the stay is needed only if manufacturer was made a party to the action on motion by the customer</li> <li>• customer requests stay within the later of: 90 days after first pleading is served, or the first scheduling order in the case</li> </ul> <p>Same definitions for “customer,” “retailer,” and “end user” as the Innovation Act (as reported)</p> <p>Same criteria as the Innovation Act for lift of the stay</p> <p>ANDA suit exception</p>	n/a	n/a	n/a

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Shifting of Attorney Fees</b>	<p>Requires a court to award attorney fees to prevailing party unless court finds that either:</p> <ul style="list-style-type: none"> <li>• nonprevailing party's litigation position and conduct are "reasonably justified in law and fact" or</li> <li>• special circumstances exist that make an award unjust (special circumstances include undue economic hardship to a named inventor)</li> </ul> <p>NO ANDA suit exception</p>	<p>On motion of the prevailing party, court must determine whether the nonprevailing party's position was "objectively reasonable in law and fact" and whether its conduct was "objectively reasonable"</p> <ul style="list-style-type: none"> <li>• If they were not, court must award reasonable attorney fees to prevailing party unless special circumstances exist that make an award unjust</li> <li>• Special circumstances include undue economic hardship to a named inventor or to an institution of higher education</li> </ul> <p>The prevailing party shall bear the burden of demonstrating that the prevailing party is entitled to an award of attorney fees</p> <p>ANDA suit exception</p>	n/a	n/a	n/a

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Attorney Fee Recovery</b>	<p>If nonprevailing party cannot pay, court shall join an interested party to pay if prevailing party shows that nonprevailing party has no substantial interest in the case other than asserting the patent</p> <p>Defendant must file initial statement expressing good faith belief that plaintiff has no substantial interest in the case other than asserting the patent</p> <p>Plaintiff must certify within 45 days of defendant's initial statement that: (a) the party has sufficient funds to pay for any potential fee award, (b) the party has substantial interest in the case other than asserting the patent, or (c) no other interested parties exist</p> <p>Court may deny motion to join interested party if: (a) interested party is not subject to service of process, or (b) joinder would deprive court of subject matter jurisdiction or make venue improper</p> <p>Court must deny motion to join interested party if: (a) party did not receive timely notice of being identified as an interested party, or (b) interested party renounces in writing and with notice to the court and parties, any ownership, right, or direct financial interest in the patent</p> <p>Exceptions for: university tech transfer organizations</p>	<p>Defendant may file initial statement expressing good faith belief that the plaintiff's primary business is asserting patents</p> <p>Plaintiff must file a certification within 45 days of defendant's initial statement that includes:</p> <ul style="list-style-type: none"> <li>• that the party has sufficient funds to pay for any potential fee award,</li> <li>• that the party's primary business is not asserting/enforcing patents,</li> <li>• identity of interested parties, or</li> <li>• no such interested parties exist</li> </ul> <p>Plaintiff must provide interested parties notice that the party may be held accountable to pay for an award of attorney fees if the plaintiff cannot satisfy the full amount of the award</p> <p>Interested parties may avoid financial liability by renouncing their interest in the patent, within 120 days of receipt of the notice above</p> <p>Interested parties may intervene in the action to contest its identification as an interested party or their liability for attorney fees</p> <p>Court may exempt interested party from liability in the interest of justice</p> <p>Exceptions for: universities, non-profit tech transfer organizations, and ANDA suits</p>	n/a	n/a	n/a

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Demand Letters</b>	“Sense of Congress” that action including litigation stemming from purposely evasive demand letter should be considered fraudulent or deceptive practice	<p>Party may not rely on evidence of pre-suit notification to establish willful infringement unless communication contains specific information</p> <p>Prohibits pre-suit notification from containing statements that:</p> <ul style="list-style-type: none"> <li>• request, demand, or offer to accept a specific monetary amount in exchange for a license, settlement, or similar agreement to resolve allegations of patent infringement; or</li> <li>• demand a specific monetary amount based on the cost of legal defense in a lawsuit concerning any asserted claim</li> </ul> <p>Defines widespread demand letter abuse as violation of FTC Act</p>	Defines a demand letter as an unfair or deceptive practice under FTC Act if wrongly and in bad faith misrepresents specific details	<p>Entity that sends 20 or more demand letters per year must disclose specific information to USPTO</p> <p>Demand letters must include specific information relating to the patent claim allegedly infringed and the party alleging infringement</p>	Defines a demand letter as a unfair or deceptive practice under FTC Act if wrongly and in bad faith misrepresents specific details

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Reforms of PTAB’s IPR and PGR Proceedings</b>	<p>Requires the Patent Trial and Appeal Board (PTAB), in inter partes review (IPR) and post-grant review (PGR) proceedings, to follow the same claim construction standard used by district courts</p> <p>Narrows the estoppel effect arising from a PGR by allowing a PGR petitioner to raise in a later civil action issues (with respect to the validity of a patent claim) that they “reasonably could have raised” during the PGR</p> <p>Prohibits IPR or PGR from being initiated unless petitioner certifies that the petitioner:</p> <ul style="list-style-type: none"> <li>• does not own and will not acquire a financial instrument that is designed to hedge or offset any decrease in the market value of an equity security of the patent owner or an affiliate of the patent owner; and</li> <li>• has not demanded payment (monetary or otherwise) from the patent owner or an affiliate of the patent owner in exchange for a commitment not to file a petition for IPR with respect to the owner’s patent, unless the petitioner has been sued for or charged with infringement of the patent</li> </ul>	<p>Requires the PTAB, in IPR and PGR proceedings, to follow the same claim construction standard used by district courts</p> <p>Narrows the estoppel effect arising from a PGR by allowing a PGR petitioner to raise in a later civil action issues (with respect to the validity of a patent claim) that they “reasonably could have raised” during the PGR</p> <p>Clarifies that the patent challenged in an IPR or PGR shall be presumed to be valid</p> <p>Allows the USPTO Director to refuse to institute an IPR or PGR proceeding “if the Director determines that institution would not serve the interest of justice;” factors relevant to such determination include:</p> <ul style="list-style-type: none"> <li>• whether the grounds of unpatentability are the same as those considered and decided in prior judicial or USPTO proceedings, and</li> <li>• whether there is another proceeding or matter involving the same patent that is pending before the USPTO</li> </ul> <p>Requires that panels convened to adjudicate PGR or IPR proceedings have no more than 1 person, if any, who participated in the decision to institute such proceeding</p>	<p>Requires the PTAB, in IPR and PGR proceedings, to follow the same claim construction standard used by district courts</p> <p>Provides a presumption of validity to a previously issued claim that is challenged during an IPR or PGR proceeding</p> <p>Requires IPR/PGR petitioner to prove unpatentability of a previously issued claim “by clear and convincing evidence” (existing law is “preponderance of the evidence”)</p> <p>Provides more stringent standing requirements for IPR/PGR petitioner</p>	n/a	n/a



	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Elimination of USPTO Fee Diversion</b>	n/a	n/a	Establishes a revolving fund in which fees collected by USPTO would be deposited; such fees would be available to USPTO until expended	n/a	n/a

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Venue</b>	<p>Limited to judicial districts where:</p> <ul style="list-style-type: none"> <li>defendant has its principal place of business or is incorporated;</li> <li>defendant has committed an act of infringement of a patent in suit and has a regular and established physical facility that gives rise to the act of infringement;</li> <li>defendant has agreed or consented to be sued in the instant action;</li> <li>where inventor named on the patent in suit conducted research or development that led to the application for the patent in suit;</li> <li>a party has a regular and established physical facility that such party controls/operates and has engaged in significant research and development of, or manufactured a tangible product that is alleged to embody, the invention claimed in the patent</li> </ul> <p>General venue statute (28 U.S.C. §1391(d)) governs venue for patent cases involving foreign defendants that are not incorporated or have no regular and established physical facilities in the United States</p>	n/a	n/a	n/a	n/a

	<b>H.R. 9 Innovation Act (as reported)</b>	<b>S. 1137 PATENT Act (as reported)</b>	<b>S. 632 STRONG Patents Act</b>	<b>H.R. 1896 Demand Letter Transparency Act</b>	<b>H.R. 2045 TROL ACT</b>
<b>Small Business</b>	<p>Requires USPTO director to develop educational resources for small businesses with respect to their “concerns arising from patent infringement”</p> <p>Requires USPTO and other federal agencies to provide, through existing small business outreach programs, education and awareness on abusive litigation practices</p> <p>Requires USPTO to create and maintain a “user-friendly” section of its website in which the public may find information about filed patent cases and the patents at issue in those cases</p> <p>Requires USPTO director to conduct a study examining the economic impact of the Innovation Act on the ability of individuals and small businesses owned by women, veterans, and minorities to enforce their patent rights</p>	<p>Requires USPTO director to develop educational resources for small businesses with respect to their “concerns arising from patent infringement”</p> <p>Requires USPTO to create and maintain a “user-friendly” section of its website in which the public may find information about filed patent cases and the patents at issue in those cases</p>	<p>Requires Small Business Administration to produce a report analyzing the impact of patent ownership by small businesses and patent infringement actions against small businesses</p> <p>Requires Director of the Administrative Office to designate at least six district courts to address special issues raised in patent infringement suits against individuals or small business concerns; such courts would be required to expedite cases in which an individual or small business concern is accused of patent infringement</p>	n/a	n/a

**Source:** Congressional Research Service.

## **Author Contact Information**

Brian T. Yeh  
Legislative Attorney  
byeh@crs.loc.gov, 7-5182

Emily M. Lanza  
Legislative Attorney  
elanza@crs.loc.gov, 7-6508